15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 1 of 88 
 OBSEVA  CONFIDENTIAL  CLINICAL STUDY PROTOCOL  
 
Protocol Number:  15-OBE2109- [ADDRESS_372918] Number:  [ADDRESS_372919]:  OBE 2109  
Study Title:  A randomi zed, double -blind, placebo -controlled, phase 2b 
dose -ranging study to assess the efficacy and safety of 
OBE2109 in subjects with endometriosis associated pain.  
Short Study Title:  A phase 2b study to assess the efficacy and safety of OBE2109 
in subjects wit h endometriosis.  
Study Name:  [CONTACT_304760] : Version 1.0  
Final Protocol Date : April 25, 2016  
Study Sponsor:   
ObsEva S.A.  
12, Chemin des Aulx  
1228 Plan- Les-Ouates, Geneva / Switzerland  
Phone [PHONE_6349]  15 50  
Fax [PHONE_6350]  21 
 
Clinical Trial Director:   
Véronique Lecomte  
ObsEva S.A.  
12, Chemin des Aulx  
1228 Plan- Les-Ouates, Geneva / Switzerland  
Office p hone  [PHONE_6349]  15 56 
Mobile  phone [PHONE_6351]  28 
Fax [PHONE_6352]  743 29  21 
Medical Responsible : Elke Bestel  
ObsEva S.A.  
12, Chemin des Aulx 
1228 Plan- Les-Ouates, Geneva / Switzerland  
Office p hone  [PHONE_6349]  15 68 
Mobile phone  [PHONE_6353]  30 
Fax [PHONE_6352]  [ADDRESS_372920] Manager : Vitaliy Solskyy  
Chiltern International Ukraine LLC  
31/33, Smolenska str., block 5  
[ZIP_CODE], Kyiv, Ukraine  
Office phone: [PHONE_6354] 90  
Mobile: + 38 050 442 55 36 
Fax: [PHONE_6354] 91  

15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 2 of 88 
 OBSEVA  CONFIDENTIAL   
 
CONFIDENTIAL AND PROPRIETARY 
This protocol contains confidential and proprietary information about an investigational drug and is 
provided by [CONTACT_304708] S.A., Plan- les-Ouates, Geneva, Switzerland, for the exclusive use of the 
Investigators of this clinical study and their Health Authorities/IRBs/IECs. This confidential 
information may not be disclosed to any other person without prior written consent of ObsEva S.A. 
Note: Other ObsEva  or delegate personnel  who may be contact[CONTACT_304709] s tudy 
are listed in a separate document, which will be updated on a regular basis when necessary.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
15-OBE 2109- [ADDRESS_372921] of the study at this site and agree to the following:  
• I understand and will conduct the study according to the protocol, any approved protocol 
amendments, ICH GCP and all applicable regulatory authority requirements and national laws.  
• I will not deviate from the protocol without prior written permission from the sponsor  and prior 
review and written approval from the Institutional Review Board or Independent Ethics 
Committee, except where necessary to prevent any immediate danger to the subj ect. 
• I have read and understand fully the Investigator Brochure (IB) for OBE 2109, and I am familiar 
with the Investigational Medicinal Product (IMP) and its use according to this protocol.  
• I have sufficient time to properly conduct and complete the trial within the agreed trial period, 
and I have available an adequate number of qualified staff and adequate facilities for the 
foreseen duration of the trial to conduct the trial properly and safely.  
• I will ensure that any staff at my site(s) who are involved in the study conduct are adequately 
trained regarding the IMP, the protocol and their responsibilities. In the case of delegating any of my study responsibilities I will provide the sponsor  with a Delegation of Activities certificate.  
• I understand that som e regulatory authorities require sponsor s of clinical studies to obtain and 
supply, when required, details about the I nvestigators ownership interests in the sponsor  or the 
Investigational Medicinal Product and information regarding any financial ties with  the sponsor . 
The sponsor  will use any such information that is collected solely for the purpose of complying 
with regulatory requirements. I therefore agree to supply the sponsor  with any necessary 
information regarding ownership interest and financial ti es (including those of my spouse and 
dependent children), and to provide updates as necessary. 
 
  
   
Signature   [CONTACT_304761]  
   
   
   
 
15-OBE 2109- [ADDRESS_372922] OF ABBREVIATION S ........................................................................................... 11 
SYNOPSIS  ...................................................................................................................... 15 
1. BACKGROUND INFORMATI ON ............................................................... 25 
1.1. INTRODUCTION TO OBE2109  ........................................................................... 25 
1.2. ENDOMETRIOSIS  ................................................................................................ 25 
1.3. CONVENTIONAL TREATME NT OF ENDOMETRIOSIS  ................................ 25 
1.4. SUMMARY OF NON -CLINICAL STUDIES ....................................................... 26 
1.4.1.  Non-Clinic al Pharmacology  ................................................................................... 26 
1.4.2.  Non-Clinical Pharmacokinetics and Toxicology  .................................................... 26 
1.5. SUMMARY OF CLINICAL STUDIES  ................................................................ 27 
1.5.1.  PK/PD  ..................................................................................................................... 27 
1.5.2.  Efficacy  ................................................................................................................... 28 
1.5.3.  Safety  ...................................................................................................................... 28 
1.6. RATIONALE FOR THE C URRENT S TUDY  ...................................................... 28 
1.7. SUMMARY OF OVERALL R ISKS AND BENEFITS  ........................................ 29 
2. OBJECTIVES  ............................................................................................... 29 
2.1. EFFICACY OBJECTIVE S .................................................................................... 29 
2.1.1.  Primary  ................................................................................................................... 29 
2.1.2.  Secondary  ............................................................................................................... 29 
2.2. SAFETY  OBJECTIVES  ......................................................................................... 30 
2.3. PHARMACOKINETIC -PHARMACODYNAMIC OBJE CTIVE S ...................... 30 
3. ENDPOINTS  .................................................................................................  30 
3.1. EFFICACY ENDPOINTS ...................................................................................... 30 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 6 of 88 
 OBSEVA  CONFIDENTIAL  3.1.1.  Primary  ................................................................................................................... 30 
3.1.2.  Secondary  ............................................................................................................... 30 
3.2. SAFETY ENDPOINTS  .......................................................................................... 31 
3.3. PHARMACOKINETIC -PHARMACODYNAMIC ENDP OINTS ........................ 32 
4. STUDY DESIGN ........................................................................................... 32 
5. STUDY POPULATION  ................................................................................ 34 
5.1. SUBJECTS  ............................................................................................................. 34 
5.1.1.  Description of the target population  ....................................................................... 34 
5.1.2.  Number of subjects  .................................................................................................  34 
5.1.3.  Study region/location  .............................................................................................. [ADDRESS_372923] RUCTIONS  ................................................................................ 37 
6.2. OUTLINE OF STUDY PROCEDURES AND ASSESSMENTS  ......................... 38 
6.2.1.  Screening Period –  Study Screening visit (11±5 weeks prior to Day 1 visit)  ......... 38 
6.2.2.  Part A treatment period  ........................................................................................... 40 
6.2.3.  Part B treatment  period ........................................................................................... 43 
6.2.4.  Follow -up period without treatment – Study visits Week 28 (Day 197 ± 3 days ), 
Week 36 (Day 253 ± 3 days ) and Week 48 (Day 309 ± 3 days ) ............................ 45 
6.2.5.  Planned extension of the study ............................................................................... 47 
6.3. EFFICACY OBSERVATIONS AND MEASUREMENTS  .................................. 47 
6.3.1.  Pelvic pain  .............................................................................................................. 47 
6.3.2.  Daily activity  .......................................................................................................... 47 
6.3.3.  Uterine bleeding ...................................................................................................... 47 
6.3.4.  Analgesic use  .......................................................................................................... 48 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 7 of 88 
 OBSEVA  CONFIDENTIAL  6.3.5.  Dyspareunia (pain associat ed with sexual intercourse)  .......................................... 48 
6.3.6.  Dyschezia (pain associated with defecation)  .......................................................... [ADDRESS_372924]  ......................................................................... 62 
8.2. PROCEDURES FOR ELICI TING, RECORDING AND REPORTING ADVERSE 
EVENTS  ................................................................................................................. 63 
8.2.1.  Eliciting Adverse Events  ........................................................................................ 63 
8.2.2.  Recording of A dverse Events in the eCRF  ............................................................. 63 
8.2.3.  Reporting of Adverse Events  .................................................................................. 63 
8.3. SERIOUS ADVERSE EVEN TS ............................................................................ 64 
8.3.1.  Definitions  .............................................................................................................. 64 
8.3.2.  SAE Urgent Reporting Procedure  .......................................................................... 65 
8.4. REPORTING TO THE INDEPENDENT ETHICS COMM ITTEE S/ 
INSTITUTIONAL REVIEW  BOARDS AND REGULATOR Y AUTHORITIES  [ADDRESS_372925]/ Independent Ethics Committee Requirements  .......... 73 
10.1.4.  End of the study  ...................................................................................................... 73 
10.2.  INVESTIGATOR RESPONS IBILITIES  ............................................................... 73 
10.2.1.  Coordinating Investigator  ....................................................................................... 73 
10.3.  DATA MANAGEMENT  ....................................................................................... 73 
10.4.  STUDY MONITORING  ........................................................................................ 73 
10.5.  REVIEW COMMITTEE(S)  ................................................................................... 74 
10.5.1.  Data Monitoring Committe (DMC)  ........................................................................ [ADDRESS_372926] CONFIDENTIAL ITY .......................................................................... 74 
10.7.  QUALITY ASSURANCE  ...................................................................................... 74 
10.8.  STUDY OR SITE DISCONTINUATION  ............................................................. 75 
10.9.  RETENTION OF ESSENTI AL STUDY DOCUMENTS  ..................................... 75 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 10 of 88 
 OBSEVA  CONFIDENTIAL  11. APPENDICES  ................................................................................................... 76 
 SCHEDULE OF STUDY ASSESSMENT S ...................................................................... 77 
 MODIFIED BIBEROGLU &  BEHRMAN SYMPTOM SEVE RITY SCALE*  ....................... 78 
 ENDOMETRIOSIS HEALTH  PROFILE QUESTIONNAIR E (EHP -30) .............................. 79 
 PATIENT GLOBAL IMPRESSION OF CHANGE  ........................................................... 83 
 PI[INVESTIGATOR_304675]®  ............................................................................................. [ADDRESS_372927]  Aspartate amino Transferase 
AUC  Area U nder the Curve  
AUC (24hr)  Area Under the plasma concentration time C urve from time [ADDRESS_372928]-
dose 
AUC 0-∞ Are Under the Curve from time [ADDRESS_372929] measurable time 
AUC τ Are Under the Curve to the end of the dosing period  
mB&B  modified Biberoglu & Behrman  
BMD  Bone Mineral Density  
BMI  Body Mass Index  
BP Blood Pressure  
bpm Beats Per minute  
°C Degree Celsius  
CK Creatine Kinase  
cm Centimeter(s)  
Cmax Maximum (peak) concentration of the drug  
COC  Combined Oral Contraceptives 
CRA  Clinical Research A ssociate 
CRO  Clinical Research Organi zation  
CV Coefficient of Variation  
CYP  Cytochrome P  
DMC  Data Monitoring Committee  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 12 of 88 
 OBSEVA  CONFIDENTIAL  DXA Dual -energy X -ray Absorptiometry  
E2 Estradiol  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
eDiary  Electronic Diary  
EHP -30 Endometriosis Health Profile – 30  
EU European Union  
FAS Full Analysis Set  
FDA Food and Drug Administration  
FSH Follicle -Stimulating Hormone  
g Gram(s)  
GCP  Good Clinical Practice  
γGT Gamma -Glutamyl T ransferase  
GGT  Gamma -Glutamyl T ranspeptidase  
GLP  Good Laboratory Practice  
GMP  Good Manufacturing Practice  
(h)GnRH  (human) Gonadotropin Releasing Hormone  
hERG  human Ether -a-go-go-Related Gene  
HDL  High Density Lipoprotein  
HIV Human Immunodeficiency Virus  
hr hour 
IB Investigator Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IMP Investigational Medicinal Product  
INN International Nonproprietary Name  
[CONTACT_304762] N ormali zed Ratio 
IRB/IEC  Institutional Review Board / Independent Ethics Committee  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 13 of 88 
 OBSEVA  CONFIDENTIAL  IUD Intra -Uterine Device  
IWRS  Interactive W eb Response System  
kg Kilogram(s)  
L Liter(s) 
LDH Lactate D eHydrogenase  
LDL  Low D ensity Lipoprotein  
LEEP Loop Electrosurgical Excision Procedure  
LFT Liver Function Test  
LH Luteini zing Hormone  
LOQ Limit O f Quantification  
µmol  Micromole(s)  
MCH  Mean Corpuscular Haemoglobin  
MCHC  Mean Corpuscular Haemoglobin Concentration  
MCV  Mean Corpuscular Volume  
mg Milligram(s)  
min Minute(s)  
mL Milliliter(s)  
mmHg  Blood pressure  in millimeter of mercury  
MNT  MicroNucleus Test  
nmol  Nanomole(s)  
NOAEL  No Observed Adverse Effect level  
NRS  Numerical Rating Scale  
NSAID  NonSteroidal Anti- Inflammatory Drug  
OBE 2109 (2-Hydroxyethyl)trimethylammonium -3-[2-fluoro- 5-(2,3- difluoro- 6-
methoxybenzyloxy) -4-methoxyphenyl] -2,4-dioxo -1,2,3,4-
tetrahydrothieno[3,4- d]pyrimidine -5-carboxylate  
P4 Progesterone  
PAP Papanikolaou test  
PD Pharmaco Dynamics 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 14 of 88 
 OBSEVA  CONFIDENTIAL  PGIC  Patient Global Impression of Change  
P-GP Permeability -GlycoProtein  
PK Pharmaco Kinetics  
PPB Plasma Protein Binding  
PSF Pregnancy Surveillance Form  
PT Prothrombin Time 
PVC/Al  PolyVinyl Chloride/Aluminum  
RBC Red Blood Cell  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SERM  Selective Estrogen Receptor Modulator  
SIN Subject Identification Number  
SPRM  Selective Progesterone Receptor Modulator  
SHBG  Sex Hormone -Binding Globulin  
SLE Systemic Lupus Erythematosus  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
T1/2 Elimination half -life 
TEAE(s)  Treatment Emergent Adverse Event(s)  
TVUS  TransVaginal UltraSound  
UDS  Unscheduled DNA Synthesis  
ULN Upper Limit of Normal  
US/[LOCATION_003] [LOCATION_002] /[LOCATION_002] of America  
VdSS  Volume of distribution at Steady State  
VRS  Verbal Rating Scale  
WBC White Blood Cell  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 15 of 88 
 OBSEVA  CONFIDENTIAL  SYNOPSIS  
Study Title: A randomi zed, double -blind, placebo -controlled, phase 2b dose -ranging study to assess the 
efficacy and safety of OBE2109 in subjects with endometriosis associated pain.  
Code/ Name [CONTACT_304763]:  OBE2109  Phase of Development: 2 
 
Objectives:  
 
Efficacy  objectives   
 
• Primary  
To assess the efficacy of a range of oral doses of OBE2109 versus placebo, in reducing pelvic 
pain in subjects with moderate  to severe endometriosis pain.  
• Secondary  
To assess the efficacy  of a range of oral doses of OBE2109 versus placebo in:  
• Reducing pelvic pain on days with uterine bleeding and pelvic pain on days with no 
uterine bleeding  
• Reducing pain associated with sexual intercourse (dyspareunia)  
• Reducing pain associated with defecation  (dysch ezia)  
• Reducing difficulty  in performing  daily activities  
• Reducing subject  reported pain symptoms of endometriosis (dysmenorrhea, pelvic pain 
and dyspareunia) and physician assessed objective findings of endometriosis (pelvic 
tenderness and pelvic induration) according to the modified Biberoglu & Behrman 
(mB&B) scale  
• Reducing the use of analgesic medication to treat pelvic pain  
• Reducing incidence and intensity of uterine bleeding 
• Improving quality of life and subject perception of change  and severity  
 
Safety objectives   
• To assess the safety and tolerability of OBE2109 in subjects with endometriosis.  
 
  
 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 16 of 88 
 OBSEVA  CONFIDENTIAL  Pharmacokinetic  (PK) -pharmacodynamic  (PD)  objective s 
To assess OBE2109 PK and establish the possible relationship between OBE2109 exposure 
and pain, estradiol ( E2) level , luteinizing hormone ( LH) level  and bone mineral density  
(BMD) . 
Endpoints: 
Efficacy endpoints   
• Primary  
• Thirty percent or greater reduction  from baseline to week 12 in the mean overall pelvic 
pain score defined as the mean of daily pain scores reported during the preceding 4-
week period , assessed on a 0 –3 Verbal Rating Scale (VRS) for pelvic pain . 
• Secondary  
• Thirty percent or greater reduction  from baseline to weeks 4, 8, 16, 20, 24, 28, 32 and 
36 in the mean overall pelvic pain score defined as the mean of daily pain scores 
reported during the preceding 4 -week period , assessed on a  0–3 VRS for pelvic pain . 
• Thirty percent or greater reduction from baseline to weeks 4, 8, 12, 16, 20, 24, 28, 32 
and 36 in the mean overall pelvic pain score defined as the mean of daily pain scores 
reported during the preceding 4 -week period , assessed on a  0–10 Numerical Rating 
Scale (NRS).  
• Thirty percent or greate r reduction from baseline to weeks 4, 8, 12, 16, 20, 24, 28, 32 
and 36 in the mean pelvic pain score for days with uterine bleeding /spotting  and for 
days with no uterine bleeding during the preceding 4 -week period , assessed on a 0–10 
NRS and on a 0–3 VRS for pelvic pain.  
• The mean pelvic pain score for days with uterine bleeding /spotting , for days with no 
uterine bleeding and all days during the preceding 4 -week period , assessed on a 0-10 
NRS and on  a 0–3 VRS for pelvic pain  at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 . 
• The m ean highest pelvic pain score defined as the mean of the [ADDRESS_372930] daily pain 
scores reported during the preceding 4-week period , assessed on a 0 –10 NRS at weeks 
4, 8, 12, 16, 20, 24, 28, 32 and 36.  
• The incidence of amenorrhea defined as n o uterine bleeding or spotting only during 
the preceding 4 -week period at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36.  
• The n umber of days with uterine bleeding (spotting excluded) during the preceding 4 -
week period at weeks 4, 8, 12, 16, 20, 24, 28, 32 a nd 36.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 17 of 88 
 OBSEVA  CONFIDENTIAL  • The mean of daily dyspareunia scores reported during the preceding 4-week period , 
assessed on a 0-10 NRS and a 0–3 VRS for dyspareunia  at weeks 4, 8, 12, 16, 20, 24, 28, 
32 and 36.  
• The mo nthly dyschezia pain score defined as the mean of weekly dysc hezia pain scores 
reported during the preceding 4 -week period , assessed on a 0 –10 NRS at weeks 4, 8, 
12, 16, 20, 24, 28, 32 and 36.  
• The u se of analgesics for pelvic pain during the preceding 4 -week period at  weeks 4, 8, 
12, 16, 20, 24, 28, 32 and 36.  
• The number of days of analgesic use for pelvic pain during the preceding 4 -week period 
at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36.  
• The number of days with pelvic pain during the preceding 4 -week period , assessed on 
a 0–3 VRS for pelvic pain at weeks 4, 8,  12, 16, 20, 24, 28, 32 and 36.  
• The number of days with moderate to severe pelvic pain during the preceding 4 -week 
period , assessed on a 0–3 VRS for pelvic pain at  weeks 4, 8, 12, 16, 20, 24, 28, 32 and 
36. 
• The mean of  scores for  difficulty in performing  daily activity reported during the 
preceding 4 -week period , assessed  on a  0-10 NRS scale at weeks 4, 8, 12, 16, 20, 24, 
28, 32 and 36.  
• The severity of subject  assessed symptoms (dysmenorrhea, non -menstrual pelvic pain 
and dyspareunia) and physician assessed objective findings ( pelvic tenderness and 
pelvic induration ) according to the mB&B  scale  at screening and weeks 12, 24 and 36.  
• The Endometriosis Health Profile -30 (EHP-30) score  at weeks 12, 24 and 36.  
• The Patient Global Impression of Change (PGIC) score at weeks 12, 24 and 36 .  
• The patient’s impression of severity  over the preceding 4 -week period  at weeks 4, 8, 
12, 16, 20, 24, 28, 32 and 36.  
Safety endpoints  
• Change from baseline to weeks 12, 24 and 48  in BMD assessed by [CONTACT_751] -energy X -ray 
absorptiometry (DXA) for femoral neck, hip and spi[INVESTIGATOR_050].  
• Treatment emergent adverse events (TEAEs) frequency and severity.  
• Changes in clinical laboratory assessments (haematology, coagulation parameters,  
biochemistry, ho rmones, lipi[INVESTIGATOR_303648]) from baseline to weeks 4, 8, 12,  16, 20,  
24, 28 and 36.  
• Any pathological changes from baseline in the endometrium as assessed by [CONTACT_304710] 12 and 24 (and week 36 only if no 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 18 of 88 
 OBSEVA  CONFIDENTIAL  endometrial biopsy was obtained at week 24 or diagnosis  at week 24 was different 
from “benign endometrium” ).  
• Change from baseline in any other safety parameter including weight, vital signs, 
gynecological assessment,  breast assessment and endometrial t hickness.  
Pharmacokinetic -pharmacodynamic endpoints  
• Plasma levels of OBE 2109  and its metabolite  KP017 measured pre -dose and 1 .5–[ADDRESS_372931] -dose at weeks 8, 12, 
20 and 24  visits . 
Study Design:  The study is a prospective, dose -finding, randomi zed, parallel group, double -blind , 
placebo -controlled  phase 2b study investigating the efficacy  and safety of OBE2109 in the treatment of 
women with endometriosis -associated pain . 
The study duration (from the Screening visit to  the End -of-Study visit) will be  up to [ADDRESS_372932].  
The study starts with a n 11±[ADDRESS_372933] will be randomized to one of 6 treatment groups: placebo, fixed -dose groups at 50, 75 , 100 and 
200 mg daily and a titrated -dose group. After randomization, a 24 -week active treatment period, 
composed of 2 periods of 12 week s each (Part A and Part B) and a subsequent 24-week treatment- free 
period will follow.   
In the placebo group, the placebo will be provided for 12 weeks (Part A) after which all placebo subjects 
will be crossed -over on to active treatment (100 mg daily) for a further 12 weeks (Part B).  
In the titrated -dose arm, all subjects will start on 75 m g daily for 12 weeks (Part A) after which the dose 
will be titrated up or down to 100 or 50 mg, or remain at the same dose  for the following 12 weeks 
(Part B). Up - or down -titration will depend on the mean of serum E2 assay results  collected at weeks 4 
and 8. Serum E2 level s will not be communicated to the investigational and the s ponsor study team s to 
maintain the blind . Possible up - or down - titration will occur according to the following algorithm: 
subjects with a mean serum E2 level of <20 pg/mL will be down -titrated to 50 mg daily whereas subjects 
with a mean serum E2 level of >50 pg/mL will be up -titrated to 100 mg daily. Subjects with a mean 
serum E2 level  from  20 to 50 pg/mL inclusive will remain on [ADDRESS_372934] completed the Part B 
treatment period (week 24), and all data have been entered into the clinical database, cleaned and 
locked, an analysis of Part B data will be performed. The results for the study part s A and B will be 
summarized a nd described in an integrated Clinical Study Report.  
A 24-week follow -up period without treatment is planned after Part B, or -  for subjects willing to 
continue treatment with OBE2109 - an extension study will be proposed. The extension study will 
consist of a further [ADDRESS_372935].  
The extension study will be described in a separate P rotocol , and analy zed and reported in a separate  
Clinical Study Report.  
Study Population: Three  hundred and thirty  (330) women  aged 18 to 45 years inclusive  with surgically , 
and – if available – histologically confirmed pelvic endometriosis and moderate to severe 
endometriosis -associated pain , will be randomized in approximately 60 sites in the US A and in Europe,  
to one of the six following treatment groups in a 1:1:1:1:1:1 ratio:  
• OBE 2109  50mg  
• OBE 2109  75mg 
• OBE 2109  100mg  
• OBE2109 200mg  
• OBE2109 75mg titrat ion group  
• OBE2109  placebo /100 mg  
Main Eligibility Criteria:   
Inclusion Criteria  
To be eligible for inclusion into this study, the subject must fulfill all of the following criteria:  
1. The subject must provide written informed consent prior to initiation of any study related 
procedures . 
2. The subject must be a  female volunteer aged [ADDRESS_372936] had surgically , and - if available -  histologically confirmed pelvic 
endometriosis (laparoscopy, laparotomy, vaginal  fornix  or other biopsy) up to [ADDRESS_372937] has moderate to severe endometriosis -associated pain during the screening period 
defined as:  
a. At the screening visit, a score of at least [ADDRESS_372938] 2 for non -
menstrual pelvic pain for the previous month assessed with the mB&B  scale.  
b. Over two full mens trual cycle s (i.e. from day [ADDRESS_372939] 
menstruation ) finishing just before the baseline visit:  
i. Mean overall pelvic pain score s of at leas t 4 on the 0 –[ADDRESS_372940] score  for each cycle  separately, i.e. required for both cycles ; 
15-OBE 2109- [ADDRESS_372941] two days with “moderate ” or “severe”  pain on the 0–3 VRS for pelvic 
pain over the days with uterine bleeding for each cycle  separately, i.e. required 
for both cycles ; 
iii. At least two days with “moderate ” or “severe”  pain on the 0 –[ADDRESS_372942] 80 % of days during the 
two screening menstrual cycles . 
6. The s ubject has regular menstrual cycles and  the total length of the two screening menstrual 
cycles should be between [ADDRESS_372943] has a BMI ≥ 18 kg/m2 and ≤ 3 9 kg/m2 at the screening visit. 
8. If of childbearing potential, the subject agrees to use one of the following birth control methods 
during the entire treatment period of the study:  
a. Sexual abstinence ,  
b. Partner with a v asectomy with  confirmed azoospermia , 
c. Double non -hormonal  barrier contraception such as condom or d iaphragm each 
combined with spermicide . 
9. If of non -childbearing potential, the subject must have had tubal ligation sterilization at least 
two months before the screening visit. 
10. The subject must be able to communicate well with the I nvestigator and research staff and to 
comply with the requirements of the study protocol.  
 
Exclusion Criteria  
To be eligible for inclusion in this study the subject must not  meet a ny of the following criteria:  
1. The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the 
treatment period of the study.  
2. The subject is less than [ADDRESS_372944] -abortion/miscarriage at the 
time of entry into the screening period.  
3. The subject had an interventional surgery for endometriosis performed within a period of [ADDRESS_372945] ha d a tubal sterilizatio n which was performed with ESSURE™ . 
6. The s ubject has an in situ copper intra- uterine device ( IUD) or an IUD with progestogen.  
7. The subject had endometrial ablation  resulting in amenorrhea . 
15-OBE 2109- [ADDRESS_372946] is likely to require treatment during the study OR received treatment within a 
specified period prior to screening with any of the medications listed below:  
a. Gonadotropin releasing hormone (GnRH) antagonists   [ADDRESS_372947] injections/3 -month depot injections   3 months/6 months  
c. Danazol        3 months  
d. Oral contraceptives and other sex hormones    1 month  
e. Depot contraceptives       6 months  
f. Selective Progesterone Receptor Modulators ( SPRMs ), 
 Selective Estrogen  Receptor Modulators ( SERMs ) 
 and a romatase inhibitors      3 months  
g. Long acting analgesics  (i.e. requiring less than  
 once daily dosing)       1 day  
h. Systemic glucocorticoid treatments  
 for acute diseases (not depot)      [ADDRESS_372948] has a history of or current systemic glucocorticoid therapy for treatment of chronic 
diseases (e.g. Systemic Lupus Erythematosus (SLE), rheumatic arthritis) .  
11. The subject did not respond to prior treatment with GnRH agonists or GnRH antagonists for 
endometriosis . 
12. The subject has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin levels ≥ 2 times the upper limit of normal OR gamma -glutamyl transpeptidase (GGT)  
level  ≥ [ADDRESS_372949] had/has clinically significant findings from a Papanikolaou ( PAP) smear performed 
within the past 12 months or at the screening visit  which will require  surgical intervention ( e.g. 
Loop electrosurgical excision procedure ( LEEP ) or cervical conisation ). 
16. The subject has chronic pelvic pain that , in the opi[INVESTIGATOR_689], is not caused by 
[CONTACT_304711] , or that would interfere 
with the assessment of endometriosis related pain.  
17. The subject has any other clinically significant gynecologic al condition identified on screening 
transvaginal ultrasound ( TVUS ) or endometrial biopsy  which might interfere with the study 
efficacy and safety objectives . However,  uterine fibroids (as long as uterus size ≤ 12 weeks, i.e. 
equivalent gestational weeks) an d adenomyosis  are allowed . 
18. The subject has a history of, or known osteoporosis or other metabolic bone disease.  
15-OBE 2109- [ADDRESS_372950] has current problem with alcohol or drug abuse (including painkiller abuse).  
22. The subject has been administered with any e xperimental drug in the [ADDRESS_372951] (s) (IMP) : OBE2109  50mg , 75mg and 100 mg tablets or placebo  
tablet s for oral administration .  
Data Analysis and Statistics: 
Descriptive statistics will be performed on relevant screening and baseline data (i.e. data collected prior 
to the treatment administration) and on demographic characteristics for each treatment group and 
overall.  The o ther parameters will be individually listed. All measured as well as derived efficacy and 
safety endpoints will be summarized by [CONTACT_304712], and 
for each time point if applicable.  
Data for the 75mg group and  75mg titrated group will be combined for the analyses of the Part A data.  
All statistical hypothesis tests and confidence intervals will be two sided, using a t ype I error rate of 
0,05. No adjustment for multiple comparisons will be used for this study.  
o Efficacy analysis methodology  
Mean overall pelvic pain scores will be calculated separately for the VRS  and NRS  by [CONTACT_304713] 4 -week periods and dividing by [CONTACT_304714]  (i.e. nominally 28 days  if no missing data ). 
Mean pelvic pain scores on uterine bleeding days and non -uterine bleeding days will be calculated by 
[CONTACT_304715] 4 -week periods (uterine bleeding 
days will be defined as those days on which the subject records any uterine bleeding or spotting in the 
subject eDiary) and dividing by [CONTACT_304716] . Both the total number of 
non-missing days in the 4 -week period ( i.e. nominally 28 days if no missing data ) and the number of 
non-missing uterine bleeding day s/non -uterine bleeding days will be considered.  
Comparisons between each individual active arm versus the placebo arm will be made  for the analysis 
of Part A of the study  (except the 75mg g roup and 75mg titrated group  which  will be combined) . In 
addition, an overall test for dose response will be conducted using all treatment arms. The coefficients 
for this contrast will be defined assuming a linear response on a log (dose+1) scale.  Analyses of Part B  
study data  will be fully described in the s tatistical analysis plan.  
The analysis of the primary endpoint will be conducted via a generalized linear model for binary data 
with repeated (correlated) measures, fitted using generalized estim ating equations (a marginal model) , 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 23 of 88 
 OBSEVA  CONFIDENTIAL  with the model including terms for treatment group, 4-week  period , baseline and the interactions 4-
week  period *treatment, 4-week  period *baseline.  
In general, between -group comparisons for continuous endpoints will be ana lyzed via (repeated 
measures) analysis of (co) -variance (repeated measures mixed models) or Wilcoxon Rank Sum tests, 
subject to the underlying distribution of the data. Between -group comparisons for binary endpoints will 
be analyzed via generalized linear model s (with repeated measures) and chi-squared tests. Between -
group comparisons for count data ( e.g. number of day s) will also be analyzed via generalized linear 
models (with repeated measures).   
It is not certain whether the continuous endpoints will be normally or log -normally distributed, and/or 
whether an absolute or proportional change in endpoints will be observed. If deemed necessary , the 
data will be log transformed prior to the analysis. The subsequent results (mean differences and 
corresponding c onfidence intervals) will be back transformed and hence reported in terms of ratios of 
geometric means.  
o Safety analysis methodology  
Extent of exposure and compliance will be evaluated.  
The safety and tolerability profile will be assessed versus baseline co nditions and differences between 
treatment groups and descriptive statistics will be produced, where applicable.  
o Pharmacokinetic analysis methodology  
For descriptive statistics of plasma concentrations mean (arithmetic and geometric), standard 
deviation, median, first and third  quartiles, minimum, maximum, coefficient of variation (CV%) and 
number  of observations  will be provided . Concentrations below t he limit of quantification  (LOQ ) will be 
assigned a value of zero . 
o Pharmacodynamic analysis methodology  
Possible PK -PD relationships will be investigated graphically and through statistical modeling.  
o Missing data handling  
Summary statistics will be based primarily on non -missing values. For hypothesis tests, estimates  and 
confidence in tervals, missing values for continuous efficacy endpoints analyzed via likelihood methods 
(e.g. repeated measures mixed models) will not be directly imputed as they are handl ed within the 
analysis itself, under the assumption that the model specification is correct and that the data is missing 
at random.  In addition, missing values for endpoints analyzed via generalized estimating equations will 
not be directly imputed as they  are handled under the assumption that the model specification is 
correct and the data is missing  completely  at random. Sensitivity analyses may be conducted to check 
the robustness of the analysis results under alternative assumptions with regards to miss ing data.  
Further details on the handling of missing values, including the rules applied to incomplete 
questionnaires (including incomplete diary entries) and any planned sensitivity analyses will be defined 
in the Statistical Analysis Plan.  
15-OBE 2109- [ADDRESS_372952] 12 -week period (Part A), an interim analysis of Part A data to 
assess the efficacy and safety parameters will be performed. The OBE2109 75mg group and OBE2109 
75mg tit rated group will be pooled for the analy sis of the Part A data.  
15-OBE 2109- [ADDRESS_372953] common gynecological  diseases ( 1). It is defined as the presence of 
endometrial -like tissue outside the uterus . The condition is predominantly found in women in their 
reproductive years and disappears spontaneously after menopause. A chronic, inflammatory reaction, 
induced by [CONTACT_304717], results in infertility ( 2) and a variety of pain symptoms 
including dysmenorrhea, dyspareunia, chronic pelvic pain, dysuria and dyschezia ( 3, 4). Often the pain 
associated with endometriosis is cyclical in nature and reflec ts the response of the ectopic endometrial -
like tissue to cycling reproductive hormones, particul arly estrogens.  
Endometriosis represents a significant economic burden  (5). Indeed, the treatment of endometriosis -
associated pain and infertility leads to significant direct costs. In addition, t he endometriosis -associated 
signs and symptoms have a significant impact on health related quality  of life and often lead to work 
absenteeism and productivity loss (6), especially as the diagnosis of endometriosis is often d elayed (7, 
8, 9).    
Guidelines for the management of endometriosis have been published ( 10,11 ) and several  medical and 
surgical therapi[INVESTIGATOR_304676]. However, an effective and well -tolerated treatment of endometriosis 
remains a largely unmet medical need . 
1.3. CONVENTIONAL TREATMENT OF ENDOMETRIOSIS  
The principal objective in treating endometriosis is symptom -relief management. Treatment options for 
women with endometriosis -associated pain are diverse and consist of analgesic therapi[INVESTIGATOR_014], hormonal 
therapi[INVESTIGATOR_014], conservative or minimal invasive surgery, or a combination of these ( 4). Hormonal therapi[INVESTIGATOR_304677], prevention of cyclic endometrium growth, and abo lition of menstruation 
through achievement of a stable steroid hormone milieu, based on the concept that the response of the 
eutopic and ectopic endometrium is substantially similar ( 12, 13). 
Combined oral contraceptives (COCs), although not approved for the treatment of endometriosis -
associated pain, are often used as initial therapy. Their administration  results in anovulation, reduction 
of menstrual blood flow, decidualization of endometriotic lesions, down regulation of cell proliferation and enhanced apoptosis in the endometrium ( 14). However, over time many women on COCs no longer 
have adequate pain relief and require second- line therapy ( 15).  
Progestin monotherapy can be efficacious for the reduction in endometriosis -associated pain as it 
induces anovulation and a hypoestrogenic state via suppression of pi[INVESTIGATOR_304678]. Progestins also have direct effects on the endometrium, causing decidu alization of eutopic and ectopic 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 26 of 88 
 OBSEVA  CONFIDENTIAL  endometrium leading to atrophy of the endometriotic implants ( 16). However, progestin monotherapy 
is often associa ted with breakthrough bleeding, alterations in mood, weight gain, and breast tenderness 
(17).  
Other therapi[INVESTIGATOR_304679] -associated pain are often limited 
by [CONTACT_304718]. For example, GnRH agonists lead , through a constant stimulation of the 
GnRH receptor at the pi[INVESTIGATOR_46604] , to its desensitization and ultimately to suppression of ovulation 
and a marked reduction of  serum estrogen levels; thus their use is associated with significant 
hypoestrogenic side- effects. Short -term effects include menopausal symptoms such as hot flashes, 
vaginal dryness, loss of libido and emotional lability , and their long- term use is limited by [CONTACT_304719] (BMD) reduction ( 18). 
GnRH antago nists are a promising new potential treatment option that is hypothesized to allow dose -
dependent control of E2 levels reducing endometriosis implants and endometriosis -associated pain 
without hypo- estrogenic side- effect including hot flashes and BMD  loss (18). 
1.4. SUMMARY OF NON-CLINICAL STUDIES  
1.4.1.  Non-Clinical Pharmacology 
OBE2109 shows potent affinity for the GnRH rec eptors in different species particularly the human 
GnRH (hGnRH) receptor  and acts as an antagonist in vitro  (hGnRH Ki= 27.4nM) . The affinity of KP017, 
the main metabolite of OBE2109, to hGnRH receptor was shown to be 5 fold lower (Ki=127 nM).  
Specific effect s on the endometrium were observed during in vivo studies, with OBE2109 acting through 
suppression of estrogen dependent endometrial proliferation in a rat autograft  endometriosis model. It 
is noteworthy that clinical signs such as amenorrhea were also observed in toxicology work in the 
cynomolgus monkey.  
Safety pharmacology studies did not show any adverse effects on the central nervous, respi[INVESTIGATOR_304680] a clinical setting.  
1.4.2.  Non-Clinical  Pharmacokinetics and Toxicology  
 Pharmacokinetics  
OBE2109 was rapi[INVESTIGATOR_304681] a generally dose- proportional manner. The volume of distribution and plasma clearance were low. 
OBE2109 is highly bound to plasma proteins (>95%) across a range of species with no concentration 
dependent changes. In human plasma, the major binding protein for OBE2109 was albumin. It does not 
exhibit blood partitioning.  
Tissue distribution of radiolabeled OBE2109 was widespread; there was no indication of unusual 
distribution or accumulation to tissues . Radioactivity was also detected in fetal tissues and milk.  
The major route of biotransformation of OBE2109 was the oxidative O -demethylation t o KP017 
(produced via CYP2C9 metabolism) which was observed in hepatocytes of all tested species. The in 
vivo metabolic pathway of OBE2109 in mice, rats and monkeys was comparable to the in vitro data. 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 27 of 88 
 OBSEVA  CONFIDENTIAL  Excretion of radioactivity  from radiolabeled OBE2109 was predominantly via  feces in both rats and 
monkeys . 
Pharmacokinetic interaction studies in vitro indicated that drugs possibly co -administered in clinical 
settings (NSAIDs) did not affect the plasma protein binding of OBE2109. An in vitro CYP induction 
study indicated that OBE2109 could induce CYP3A4/[ADDRESS_372954]. During pi[INVESTIGATOR_304682], dose levels of 200 and 10 mg/kg/day OBE2109 were shown to be the NOAEL in the main toxicology species rat (26 -week daily oral administration) and monkey (39- week daily oral 
administration), respectively, and resulted in therapeutic indices (based on total / unbound exposure) for a human dose of 200 mg/day of 6.7 / 4.6 and 0.8 / 3.6, respectively.  
Reproductive toxicity studies, especially fertility studies and  embryo -foetal development studies in 
rabbits, were limited in dose by [CONTACT_16682] -GnRH effects of OBE2109 preventing conception or leading to 
total litter loss. The effects of OBE2109 on conception were reversible, and rabbit embryo -foetal studies 
showed expected pharmacological activity and no adverse reprotoxic/teratogenic effect.  
OBE2109 was not genotoxic or phototoxic.  
Taken together, the data in this nonclinical package have shown OBE2109 to be an oral ly available , 
potent, selective GnRH receptor antagon ist. Anti- GnRH effects have been demonstrated in a range of 
pharmacology studies, both in vitro and in vivo, and these also dominate the findings in the toxicology 
studies. Toxicology evaluation in mice, rats, dogs and monkeys confirmed exaggerated pharmac ological 
activity but no overt toxicity. No genotoxicity or unexpected reproduction toxicology findings in rats 
and rabbits were seen.  
In conclusion, the nonclinical package confirms that OBE2109 supports clinical dosing regimens up to 
200 mg per day . 
1.5. SUM MARY OF CLINICAL STUDIES  
The efficacy, safety and PK of OBE2109 were investigated  by [CONTACT_304720] (Kissei 
Pharmaceutical Co., LTD. from Japan) in one  Phase 1 study (Study KLH1101)  in Japanese and 
Caucasian volunteers in single and multiple doses up to 400 mg , and in three  Phase 2 studies (Stud ies 
KLH1201, KLH1202 and KLH1203)  in Japanese endometriosis patients at doses up to [ADDRESS_372955] been exposed to OBE2109 for a duration of up to 3 months.  
1.5.1.  PK/PD  
OBE2109 was evaluated in a Phase 1 single/repeated -dose study (Study KLH1101) in which Japanese 
and Caucasian pre-  and post -menopausal women received single doses of OBE2109 from  12.5 t o 400 
mg and repeated doses of 100 to 400 mg once daily for 7 days under fed and fasted conditions. OBE2109 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 28 of 88 
 OBSEVA  CONFIDENTIAL  was safe and well -tolerated, showed linear pharmacokinetics, a half -life of about 15–[ADDRESS_372956] of food on the extent of absorption and there was a dose -dependent suppression 
of LH, FSH and E2.  
1.5.2.  Efficacy  
The clinical evidence for the efficacy of OBE2109 is deri ved from t he results of three  Phase 2 studies.  
In a Phase 2 clinical study in patients with endometriosis (Study KLH1201), 50 or 200 mg OBE2109 
was orally administered once daily for 8 weeks. OBE2109 improved endometriosis symptoms and 
continuously suppre ssed E2 in a dose -dependent manner.  
In a Phase 2 clinical study in patients with endometriosis (Study KLH1202), 50, 100, or [ADDRESS_372957] for 12 weeks. OBE2109 
significantly reduced endometrios is pain symptoms compared with placebo.  
In a Phase 2 clinical study in patients with endometriosis (Study KLH1203), [ADDRESS_372958] frequent side effects were disturbances of the menstrual cycle (Metrorrhagia) and hypoestrogenic AEs (Hot flushes).  
In some subjects, an increase in transaminase values was observed under treatment . However this 
increase was generally reversible under treatment, exceeded 3× ULN in only one single case and was 
never associated with any increase in b ilirubin . 
The vast majority of AEs were reported as being of “mild” severity, only few events were reported as 
being of “moderate” severity and only one  AE (unrelated to study drug) was reported as of “severe” 
intensity.  
1.6. RATIONALE FOR THE CURRENT S TUDY  
OBE2109 has been shown  to suppress in a dose dependent manner LH and E2 and to significantly 
reduce endometriosis -associated pain in Japanese women at doses between 50 and 200 mg daily , with a 
good safety and tolerability profile. Furthermore, after administration of 50 or 75 m g per day, median 
E2 levels were in the range of 20 –50 pg/mL , which is the range exp ected to provide relief from 
endometriosis symptoms while maintain ing BMD  (19, 20), suggesting 50 or 75 mg could be an optimal 
dose in Japanese patients. It is anticipated that the US/European population will have a higher average 
weight and therefore a dose range of 50–[ADDRESS_372959] s with mean E2 levels in the range 20 –50 pg/ml to see if 
this provides any clinical advantages over a fixed dose regimen.  
The purpose of the current  study is therefore to evaluate the safety an d efficacy of OBE2109 in non-
Japanese (primarily US A and European) women with surgically confirmed endometriosis and 
associated pelvic pain. It is a Phase 2b double -blind, placebo controlled dose ranging study with the aim 
of establishing doses , regimens  and endpoints to be used in pi[INVESTIGATOR_304683] [ADDRESS_372960] which has been shown to significantly reduce endometriosis 
related pain in Japanese patients via dose dependent suppression of LH, FSH and E2. It has a half -life 
consistent with once daily dosing. Efficacy was demonstrated at daily doses of 50– [ADDRESS_372961] commonly reported AEs in the Phase 2 studies 
were metrorrhagia and hot flushes which are related to the biological activity of OBE2109.  
There were no clinically relevant findings in laboratory measurements, vital signs or ECG rec ordings. 
The administration of OBE2109 results in infrequent, transient, moderate and not dose -related increases 
in transaminase levels which were not associated with any change in bilirubin levels.   
In conclusion, OBE2109 has a favorable  benefit/risk ratio and represents a potentially useful therapy for 
treating endometriosis  related pain . 
 
2. OBJECTIVES  
 
2.1. EFFICACY OBJECTIVES  
 2.1.1.  Primary  
• To assess the efficacy of a range of oral doses of OBE2109 versus placebo, in reducing 
pelvic pain in subjects with moderate to severe endometriosis pain . 
 
2.1.2.  Secondary  
To assess the eff icacy  of a range of oral doses of OBE2109 versus placebo in : 
 
• Reducing pelvic pain on days with uterine bleeding and pelvic pain on days with no 
uterine bleeding  
• Reducing pain associated with sexual intercourse  (dyspareunia)   
• Reducing pain associated with defecation (dyschezia)  
• Reducing difficulty in  performing daily activites  
• Reducing subject  reported pain symptoms of endometriosis (dysmenorrhea, pelvic pain 
and dyspareunia)  and physician assessed objective findings of endometriosis (pelvic 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 30 of 88 
 OBSEVA  CONFIDENTIAL  tenderness and pelvic induration) according to the modified Biberoglu & Behrman 
(mB&B) scale ( 22, APPENDIX B ) 
• Reducing the use of analgesic medication to treat pelvic pain  
• Reducing incidence and intensity of uterine bleeding  
• Improving quality of life and subject perception of change  and severity  
 
2.2. SAFETY  OBJECTIVES  
• To assess the safety and tolerability of OBE2109 in subjects with endometriosis.  
 
2.3. PHARMACOKINETIC- PHARMACODYNAMIC OBJE CTIVE S 
• To assess OBE2109 PK and establish the possible relationship between OBE2109 
exposure and pain, E2 level , LH level  and bone mineral density  (BMD) . 
3. ENDPOINTS  
3.1. EFFICACY ENDPOINTS  
 
3.1.1.  Primary  
• Thirty percent  or greater reduction from baseline to week 12 in the mean overall pelvic 
pain score defined as the mean of daily pain scores reported during  the preceding  4-
week period assessed on a 0–3 Verbal Rating Scale (VRS) for pelvic pain . 
 
3.1.2.  Secondary  
• Thirty percent or greater reduction from baseline to weeks 4, 8, 16, 20, 24, 28, 32 and 
36 in the mean overall pelvic pain score defined as the mean of daily pain scores 
reported during the preceding 4 -week period , assessed on a 0– 3 VRS  for pelvic pain.  
• Thirty percent or greater reduction from baseline to weeks 4, 8, 12, 16, 20, 24, 28, 32 
and 36 in the mean overall pelvic pain score defined as the mean of daily pain scor es 
reported during the preceding 4- week period , assessed on a 0–10 Numerical Rating 
Scale ( NRS). 
• Thirty percent or greater reduction from baseline to weeks 4, 8, 12, 16, 20, 24, 28, 32 
and 36 in the mean pelvic pain score for days with uterine bleeding/spotting and for days with no uterine bleeding during the preceding 4- week period , assessed on a 0 –10 
NRS and on a 0 –3 VRS for pelvic pain. 
• The mean pelvic pain score for days with uterine bleeding/spotting, for days with no 
uterine bleeding and a ll days during the preceding 4 -week period , assessed on a 0 –10 
NRS and on a 0 –3 VRS for pelvic pain  at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 . 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 31 of 88 
 OBSEVA  CONFIDENTIAL  •  The mean highest pelvic pain score defined as the mean of the [ADDRESS_372962] daily pain 
scores reported during the  preceding 4- week period, assessed on a 0 –10 NRS at weeks 
4, 8, 12, 16, 20, 24, 28, 32 and 36.  
•  The incidence of amenorrhea defined as no uterine bleeding or spotting only during the 
preceding 4- week period at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36.  
• The number of days with uterine bleeding (spotting excluded) during the preceding 4 -
week period at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36. 
•  The mean of daily dyspareunia scores reported during the preceding 4- week period, 
assessed on a 0–10 NRS and a 0– 3 VRS for dyspareunia at weeks 4, 8, 12, 16, 20, 24, 
28, 32 and 36.  
•  The monthly dyschezia pain score defined as the mean of weekly dyschezia pain scores reported during the preceding 4 -week period, assessed on a 0 –10 NRS at weeks 4, 8, 
12, 16, 20, 24, 28, 32 and 36 . 
• The use of analgesics for pelvic pain during the preceding 4 -week period at  weeks 4, 8, 
12, 16, 20, 24, 28, 32 and 36. 
• The number of days of analgesic use for pelvic pain during the preceding 4- week period  
at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36.  
•  The number of days with pelvic pain during the preceding 4 -week period, assessed on 
a 0–3 VRS for pelvic pain at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36.  
•  The number of days with moderate to severe pelvic pain during the preceding 4- week 
period, assessed on a 0– 3 VRS for pelvic pain at weeks 4, 8, 12, 16, 20, 24, 28, 32 and 
36. 
•  The mean of scores for difficulty  in performing  daily activity reported during the 
preceding 4- week period, assessed on a 0– 10 NRS scale at weeks 4, 8, 12, 16, 20, 24, 
28, 32 and 36  
• The severity of subject assessed symptoms (dysmenorrhea, non -menstrual pelvic pain 
and dyspareunia) and physician assessed objective findings ( pelvic tenderness and 
pelvic induration ) according to the mB&B scale at screening and weeks 12, 24 and 36.  
• The Endometriosis Health Profile -30 (EHP -30) score ( 23, APPENDIX C ) at weeks 12, 
24 and 36.  
• The Patient Global Impression of Change (PGIC ) score ( 24, 25, APPENDIX D) at 
weeks 12, 24 and 36.  
• The patient’s impression of severity over the preceding 4 -week period  at weeks 4, 8, 
12, 16, 20, 24, 28, 32 and  36. 
 
3.2. SAFETY ENDPOINTS  
• Change from baseline to weeks 12, 24 and 48 in BMD assessed by [CONTACT_751] -energy X -ray 
absorptiometry (DXA) for femoral neck, hip and spi[INVESTIGATOR_050] .  
• Treatment emergent adverse events (TEAEs)  frequency and severity.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 32 of 88 
 OBSEVA  CONFIDENTIAL  • Changes in clinical laboratory assessments (haematology, coagulation parameters, 
biochemistry, hormones, lipi[INVESTIGATOR_303648]) from baseline to weeks 4, 8, 12, 16, 20, 
24, 28 and 36.  
• Any pathological changes from baseline in the endometrium as assessed by [CONTACT_304721] 12 and 24 (and week 36 only if no endomet rial biopsy was obtained at week 24 or  diagnosis at week 24 was di fferent from 
“benign endometrium” ).  
Change from baseline in any other safety parameter including weight, vital signs, gynecological assessment , breast assessment and endometrial thickness.  
 
3.3. PHARMACOKINETIC- PHARMACODYNAMIC ENDP OINTS  
• Plasma levels of OBE2109 and its metabolite KP017 measured pre- dose and 1.5 –2hrs  
post-dose on Day 1, pre -dose at week s [ADDRESS_372963] -dose at weeks 8, 12, 
20 and 24 visits. 
 
4. STUDY DESIGN 
This is a prospective, dose -finding, randomi zed, parallel group, double -blind, placebo- controlled phase 
2b study investigating the efficacy and safety of OBE2109 in the treatment of women with 
endometriosis -associated pain.  
The study duration (from the Screening visit to the End -of-Study visit) will be up to [ADDRESS_372964].  
The study starts with a n 11±[ADDRESS_372965] will be randomized to one of 6 treatment groups: placebo, fixed- dose groups at 50, 75, 100 and 
200 mg daily and a titrated- dose group. After randomization, a 24- week active treatment period, 
composed of 2 periods of 12 weeks each (Part A and Part B) , and a subsequent 24- week treatment -free 
period will follow.  
A schematic of the study design is shown in Figure 1.  
  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 33 of 88 
 OBSEVA  CONFIDENTIAL  Figure 1: Study design 
 
 
In the placebo group, the placebo will be provided for 12 weeks (Part A) after which all placebo subjects 
will be crossed -over on to active treatment (100 mg daily) for a further 12 weeks (Part B).  
In the titrated -dose arm, all subjects will start on 75 mg daily for 12 weeks (Part A) after which the dose 
will be titrated up or down to 100 or 50 mg , or remain at the same dose for the following 12 weeks (Part 
B). Up - or down- titration will depend on the mean of serum E2 assay results collected at weeks 4 and 
8. Serum E2 level s will not be communicated to the investigational and the sponsor  study team s to 
maintain the blind . Possible up-  or down-  titration will occur according to the following algorithm: 
subjects with a mean serum E2 level of <20pg/mL will be down- titrated to 50 mg daily whereas subjects 
with a mean  serum  E2 level of >50 pg/mL will be up- titrated to 100 mg daily. Subjects with a mean 
serum E2 level fro m 20 to 50 pg/mL inclusive will remain on 75 mg daily. Mean serum E2 level will 
be defined as the mean of the serum E2 assay results collected at week 4 and week 8.  
An Interactive Web Response System (IWRS)  will be used to allocate  the appropriate treatment .  
After all subjects have completed the first [ADDRESS_372966] completed the Part B treatment period (week 24), and all data have been entered into the clinical database, cleaned and locked, a n 
analysis of Part B data will be performed. The results for the study part s A and B will be summarized 
and described in a n integrated Clinical Study Report.  
A 24-week follow -up period without treatment is planned after Part B, or -  for subjects willing to 
continue treatment with OBE2109 -  an extension study will be proposed. The extension study will 
consist of a further [ADDRESS_372967] agree to non- hormonal barrier contraception 
from screening to the end of treatment period.  
5.1.2.  Number of subjects  
Three hundred and thirty (330)  randomi zed subjects are planned in total ( approximately 55 subjects per 
group).  
5.1.3.  Study region/location  
Approximately [ADDRESS_372968] fulfill  all of the following criteria:  
1.  The subject must provide written informed consent prior to initiation of any study related 
procedures.  
2. The s ubject must be a female volunteer aged [ADDRESS_372969] had surgically and  - if available  - histologically confirmed pelvic 
endometriosis (laparoscopy, laparotomy, vaginal fornix or other biopsy) up to [ADDRESS_372970] has moderate to severe endometriosis- associated pain during the screening period 
defined as:  
a. At the screening visit, a score of at least [ADDRESS_372971] 2 for non-
menstrual  pelvic pain for the previous month assessed with the mB&B  scale.  
b. Over two full menstrual cycles  (i.e. from day [ADDRESS_372972] 
menstruation ) finishing just before the baseline visit:  
15-OBE 2109- [ADDRESS_372973] 4 on the 0 –[ADDRESS_372974] score for each cycle separately, i.e. required for both cycles ; 
ii. At least two days with “moderate” or “severe” pain on the 0– 3 VRS for pelvic 
pain over the days with uterine bleeding for each cycle separately, i.e. required 
for both cycles ; 
iii. At least two days with “moderate” or “severe” pain on the 0– [ADDRESS_372975] 80% of days during the 
two screening  menstrual cycles . 
6. The subject has regular menstrual cycles and the total length of the two screening menstrual 
cycles should be between [ADDRESS_372976] has  a BMI ≥ 18 kg/m2 and ≤ 39 kg/m2 at the screening visit.  
8. If of childbearing potential, the subject agrees to use one of the following birth control methods 
during the entire treatment period of the study:  
a. Sexual abstinence ,  
b. Partner with a vasectomy with confirmed azoospermia , 
c. Double non- hormonal barrier contraception such as condom or diaphragm each 
combined with spermicide . 
9. If of non- childbearing potential, the subject must have had tubal ligation sterilization at least 
two months before the screening visit . 
10. The subject must be able to communicate well with the I nvestigator and research staff and to 
comply with the requirements of the study protocol.  
5.2.2.  Exclusion Criteria  
To be eligible for inclusion in this study the subject must not  meet any of the following criteria:  
1. The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the 
treatment period of the study.  
2. The s ubject is less than [ADDRESS_372977] -abortion/miscarriage at the time 
of entry into the s creening period.  
3. The subject had an interventional surgery for endometriosis performed within a period of [ADDRESS_372978] ha d a tubal sterilization  which was performed with ESSURE™ . 
6. The s ubject has an  in situ  copper intra-uterine device ( IUD) or an IUD with progestogen.  
15-OBE 2109- [ADDRESS_372979] is likely to require treatment during the study OR received treatment within a 
specified period prior to screeni ng with any of the medications  listed below:  
a. Gonadotropin releasing hormone (GnRH) antagonists   [ADDRESS_372980] injections/ 3 -month depot injections   3 months/ 6 months  
c. Danazol        3 months  
d. Oral contraceptives and other  sex hormones    1 month 
e. Depot contraceptives       6 months  
f. Selective Progesterone Receptor Modulators (SPRMs),   
 Selective Estrogen Receptor Modulators (SERMs)  
 and a romatase inhibitors       3 months  
g. Long acting analgesics (i.e. requiring less than  
once daily dosing)       1 day  
h. Systemic glucocorticoid treatments  
 for acute diseases (not depot)      [ADDRESS_372981] has a history of or current systemic glucocorticoid therapy for treatment of chronic 
diseases (e.g. Systemic Lupus Erythematosus (SLE), rheumatic arthritis).  
11. The subject did not respond to prior treatment with GnRH agonists or GnRH antagonists for 
endometriosis . 
12. The s ubject has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin levels ≥ 2 times the upper limit of normal OR gamma -glutamyl transpeptidase (GGT) 
level ≥ [ADDRESS_372982] had/has clinically significa nt findings from a PAP  (Papanikolaou)  smear performed 
within the past 12 months or at the screening visit  which will require  surgical intervention (e.g.  
Loop electrosurgical excision procedure (LEEP)  or cervical conisation) . 
16. The subject has chronic pelvic pain that , in the opi[INVESTIGATOR_2511] I nvestigator,  is not caused by 
[CONTACT_304711], or that would interfere 
with the assessment of endometriosis related pain.  
17. The subject has any other clinically significant gynecologic al condition identified on screening 
transvaginal ultrasound ( TVUS ) or endometrial biopsy , which might interfere with the study 
efficacy and safety objectives. However,  uterine fibroids (as long as uterus size ≤ 12 weeks, i.e. 
equiva lent gestational weeks) and adenomyosis are allowed . 
18. The s ubject has a history of, or known osteoporosis or other metabolic bone disease. 
15-OBE 2109- [ADDRESS_372983] has current problem with alcohol or drug abuse (including painkiller abuse).  
22. The s ubject has been administered with any experimental drug in the [ADDRESS_372984] ( IMP), study  procedures and potential risks and they 
will also be informed verbally by [CONTACT_304722] . They will be instructed that they can  obtain further information from the I nvestigator at any time 
and that they are free to withdraw their consent and to discontinue their participation in the project at 
any time without prejudice.  
If the subject is willing to participate in the study, she will be requested to give written informed consent prior to conducting any of the study screening procedures after being given sufficient time to consider 
her participation and the opportunity to ask for further details. Two original copi[INVESTIGATOR_1309] t he consent form 
will be signed and personally dated by [CONTACT_36552] s ubject and the Investigator or medical delegate. One  
original  signed copy  will be kept by [CONTACT_304723]. Although nursing staff may be involved in des cribing 
the trial to a subject, the Investigator/ medical delegate  must participate in discussions with the subject 
and personally sign and date the informed consent form  (ICF) . 
The subject  will be asked if she authorize s the Investigator to notify her general practitioner of her  
participation in the trial.  
Upon signature [CONTACT_48028] , each subject will be assigned a Subject Identification Number  (SIN)  in the 
electronic Case Report Form  (eCRF ). Subject Identification Numbers will be made of 5 digits, as 
follows:  
• 1st digit: country identifier (1 to 4)  
• 2nd and 3rd digits: site identifier (01 to 99)  
• 4th and 5th digits: subject number (01 to 99)  
During the whole study, the subject will be identified using the SIN  for all documentation and 
discussion. The SIN assigned to a subject in this way must only be used for that subject.  
Should a subject drop out  from the study , the SIN  will not be re -allocated.  
15-OBE 2109- [ADDRESS_372985] will be ra ndomi zed to one  of the 
6 treatment groups  in a 1:1:1:1:1:1 ratio ( approximately 55 subjects per treatment arm)  as shown in 
Figure 1.  
Randomization will be done according to a computer -generated list. Treatment assignments will be 
obtained via the IWRS according to the randomization list. The subj ect will be allocated  a randomization 
number and a treatment kit number  via the IWRS.  The randomization number allocated to the subject 
will allow any unblinded study personal to identify the treatment group to which the subject is 
randomized. The treatment kit number  will correspond to the kit number indicated on the label of the 
study drug. Kit numbers will start from K 0001, K0002, K 0003 etc. ( 5-character s). 
At the end of Part A, to maintain the blind and prevent identification of the titrated sub jects, all subject s 
will be allocated a new treatment kit number  via IWRS for the 12- week Part B treatment period.  
Treatment will remain blinded up to the end of the study for the I nvestigator  and the subject . 
6.2. OUTLINE OF STUDY PRO CEDURES AND ASSESSME NTS  
All post -baseline visits should take place at the end of the defined period (i.e. week 4 visit should be 
scheduled at the end of week 4, week 8 visit should be scheduled at the end of week 8, etc.). Post-
baseline visits dates are calculated from Day 1 visi t date.  
6.2.1.  Screening Period  – Study Screening visit (11±5 weeks p rior to D ay 1 visit ) 
The subject will be informed of the study objectives and overall requirements, and written informed consent will be obtained before performing any study- specific procedures that are not standard of care . 
The subject will be considered as included into the study after the ICF is signed and dated by [CONTACT_304724].    
The screening period will last up to 11±[ADDRESS_372986] will be seen up to three  times . 
During this time the following study screening assessments  will be completed (see schedule of 
assessments in APPENDIX A):  
- Demographic  data , height  and weight  
- Medical history including concomitant diseases, obstetric/gynecological history  and history of 
endometriosis including diagnosis and previous treatments  
- Assessment of endometriosis pain with the m B&B scale (see APPENDIX B ) 
- Previous and current  treatments  recording  
- Physical examination  
- Vital signs ( blood pressure and heart rate)  
- Urine pregnancy test  
15-OBE 2109- [ADDRESS_372987] has no ovarian endometrioma  ≥ 7 cm in diameter  
- Gynecological examination , including the m B&B  scale (see APPENDIX B ) clinical signs 
reporting  (pelvic tenderness and pelvic induration ) 
- Endometrium biopsy  (should be performed at least [ADDRESS_372988] day of menstruation and 
sent for central assessment).  If no tissue  is available, the biopsy should be repeated as soon as 
possible in the following days. 
The endometrium biopsy is not required at the sc reening visit for subjects having performed an 
endometrium biopsy within the past 6 months of the screening visit, which shows no endometrium 
atypi[INVESTIGATOR_304684].  
- PAP smear  
A screening PAP smear is not required for subjects in whom  a PAP smear was performed within 
the 12 months prior to the screening visit and which results indicate no clinically significant 
abnormalities requi ring surgical intervention (e.g. LEEP or cervical conisation) and are available 
for source document verification.  
- Manual breast examination (by [CONTACT_23302])  
- Blood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_304685]  
- Urinary protein dipstick. 
- Contraception counselling  
The subject will receive double barrier contraception (condoms  with spermicide) if necessary.  
In addition, a limited quantity (as per Investigator’s judgement) of ibuprofen and/or 
acetaminophen/paracetamol as standard rescue medication for endometriosis related pain will be given 
to the subject at the screening visit to cover the screening period . 
The subject will be given a n eDiary with a user manual to take home and will be trained  by [CONTACT_304725]: she will be asked to record  her IMP 
intake, pelvic pain, dyspareunia, dyschezia, difficulty in performing daily activities,  uterine bleeding , 
impression of severity  and use of analgesic drug(s) including dose. These screening assessments should 
cover at least two  full menstrual cycle s (from day [ADDRESS_372989] menstruation). Subject diary 
completion s hould be started on the day of screening visit . 
The eDiary should be completed:  
- Daily, in the evening  at approximately the same time, for IMP intake, pelvic pain, dysp areunia, 
difficulty in performing  daily activities,  uterine bleeding  and use of analgesic drug(s)  including 
dose; 
- Weekly, for dyschezia pain ; 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 40 of 88 
 OBSEVA  CONFIDENTIAL  - 4-weekly , for patient ’s impression of severity .  
Any concomitant medications  taken after signature [CONTACT_304764]  
(excluding provided analgesics  taken for endometriosis related pain which will be recorded daily in the 
eDiary) . 
Any AE occurring after signature [CONTACT_304765] . 
The subject will be asked to return to the site between the first and seventh  day (inclusive) of her next 
menstrual period (the period after the 2 screening menstrual cycles ) for the Day [ADDRESS_372990]  is unable to come to the clinic for Day 1 within 
the acceptable time window (1st to 7th day inclusive of the cycle) then the subject will be allowed to start 
Day 1 in the following cycle  (again on the 1st to 7th day of the cycle) . In this case, the eligibility 
assessments should be assessed  based on the first two  cycles only. However, the eDiary recording should 
be continued daily  during the third cycle . 
6.2.2.  Part A treatment period  
During the whole study Part A, the subject will be as ked to record on her eDiary:  
- Daily, at approximately the same time each evening , her IMP intake, pelvic pain, dyspareunia , 
difficulty in performing  daily activities,  uterine bleeding and use of analgesic drug(s)  including 
dose; 
- Weekly , her dyschezia pain ; 
- 4-weekly , the patient ’s impression of severity .  
 Baseline visit – Study visit Day [ADDRESS_372991] and seventh  
day (inclusive) of starting menstruation, she  will go to the investigational site  for the following 
evaluations and tests before  drug administration:  
- Confirm inclusion/exclusion criteria  (randomization will not be postponed if the results of the 
endometrium biopsy done during the screening period  are not available on Day 1)  
- Previous and concomitant treatments recording  
- AE recording  
- Physical examination  
- Vital signs (blood pressure and heart rate)  
- Urinary protein dipstick  
- eDiary  check for good completion  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 41 of 88 
 OBSEVA  CONFIDENTIAL  - EHP -30 questionnaire (see APPENDIX C ) completion by [CONTACT_423]   
- Urine pregnancy test  
- Contraception counselling  
The subject will receive double barrier contraception (condoms with spermicide) if necessary . It will be 
provided upon need a t each subsequent visit over the duration of the study . 
In view of the invasive nature of the following assessments it is recommended to perform these upon 
confirmation from the eDiary data that the subject meets the study entry requirement and upon receipt of the screening central laboratory results and confirmation that the values meet the study entry 
requirement . The following procedures will be performed and recorded as part of the s creening/baseline 
assessments, prior to the first administration of study treatment : 
- Fasting b lood samples for haematology, coagulation parameters, c hemistry, lipi[INVESTIGATOR_805] , hormones 
and OBE2109 and KP017 pre-dose plasma levels assessments.  
- BMD  assessed by  [CONTACT_304726], hip and spi[INVESTIGATOR_050] . DXA can be performed up to [ADDRESS_372992] the administration in the  eDiary.  The analgesics provided will be used 
only as rescu e medication ; no prophylactic use of analgesics is allowed during the whole study. The 
subject will be provided as necessary with analgesics at each subsequent visit  to cover study period until 
Week [ADDRESS_372993] in the eDiary  her 
IMP intake, pelvic pain, dyspareunia , difficulty in performing  daily activities, uterine bleeding, 
dyschezia, impression of severity  and use of analgesic drug(s) including dose . 
The s ubject will take her first dose of study medication  at the study site.  
After OBE2109/placebo administration, the following procedure will be performed:  
- Post-dose PK samples  taken about 1.[ADDRESS_372994] numbers and will be 
scheduled for her next visits.  
 Study visits Week 4 ( Day 29 ± 3 days ) and Week 8 ( Day 57 ± 3 days ) 
The following tests and evaluations will be performed at week 4 Study Visit and week 8 Study Visit : 
- Previous and concomitant treatments recording  
- AE recording  
- Vital signs (blood pressure and heart rate)  
- Urine pregnancy test  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 42 of 88 
 OBSEVA  CONFIDENTIAL  - eDiary check  for good completion  
- Blood samples for haematology, coagulation parameters, c hemistry, l ipi[INVESTIGATOR_805], hormones  
- Urinary protein dipstick  
- Contraception counselling  
The following tests and evaluations will be performed at week 4 Study Visit only:  
- Pre-dose PK samples ( the approxi mate time of dose administration on previous day and time of 
taking of the PK sample will be recorded).  
- The s ubject will take her daily dose of study medication at the study site . The time of taking the 
dose will be recorded.  
The following tests and evaluation s will be performed at week 8 Study Visit only:  
- The s ubject will take her daily dose at the usual time in the morning at home.  
- Post-dose PK samples same day during the site visit (the approximate time of dose 
administration at home and time of taking of the PK  sample will be recorded)  
 Study visit Week 12 ( Day 85 ± 3 days ) – End-of-Part A visit  
The s ubject will take her last daily dose of Part A study medication at the usual time in the morning at 
home. The approximate time of dose administration and time of taking of the blood sample will be 
recorded  in the eCRF .  
The following tests and evaluations will be performed at week 12 Study Visit : 
- Assessment of endometriosis pain with the mB&B  scale (see APPENDIX B ) 
- Previous and concomitant treatments recording  
- AE recording  
- Physical examination  
- Vital signs (blood pressure and heart ra te) 
- Gynecological examination, including the mB&B  scale (see APPENDIX B ) clinical signs 
reporting ( pelvic tenderness and pelvic induration ) 
- TVUS  of uterus for measuring endometrium thickness and of ovaries for checking their 
normality . 
- Urine pregnancy test  
- Contraception counselling  
- eDiary check for good completion  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 43 of 88 
 OBSEVA  CONFIDENTIAL  - EHP -30 (see APPENDIX C ) and PGIC (see APPENDIX D ) questionnaires completion by [CONTACT_1560]    
- Post-dose PK samples (the approximate time of dose administration at home and time of taking 
of the PK sample will be recorded)  
- Blood samples for haematology, coagulation parameters, c hemistry, l ipi[INVESTIGATOR_805], hormones  
- Urinary protein dipstick  
- Endometrium biopsy , unless t he endometrium thickness in TVUS is ≤ 5 mm, in which case no 
endometrium biopsy will be necessary, as far as the screening biopsy has provided assessable 
results. Appropriate photo documentation of the endometrium thickness is mandatory  and will  
be kept in the source documents. 
- BMD  assessed by [CONTACT_304726], hip and spi[INVESTIGATOR_050] . DXA can be performed ±  [ADDRESS_372995] on her eDiary:  
- Daily , at approximately the same time each evening , her IMP intake, pelvic pain, dyspareunia , 
difficulty in performing  daily activities, uterine bleeding and use of analgesic drug(s) including 
dose; 
- Weekly , her dys chezia pain ; 
- 4-weekly , the patient ’s impression of severity .  
 Study visits Week 16 ( Day 113 ± 3 days) and Week 20 ( Day 141 ± 3 days)  
The following tests and evaluations will be performed at week 16 Study Visit and week 20 Study Visit : 
- Previous and concomitant treatments recording  
- AE recording  
- Vital signs (blood pressure and heart rate)  
- Urine pregnancy test   
- Contraception counselling  
- eDiary check for good completion  
- Blood samples for haematology, coagulation parameters, c hemistry , lipi[INVESTIGATOR_805], hormones  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 44 of 88 
 OBSEVA  CONFIDENTIAL  - Urinary protein dipstick  
The following tests and evaluations will be performed at week 16 Study Visit only:  
- Pre-dose PK samples (the approximate time of dose administration on the previous day and time 
of taking of the PK sample will be recorded) . 
- The s ubject will take her daily dose of study medication at site in the morning . The time of 
taking the dose will be recorded.  
The following tests and evaluations will be performed at week 20 Study Visit only:  
- The subject  will take her daily dose at the usual time in the morning at home. 
- Post-dose PK samples  (the approximate time of dose administration at home and time of taking 
of the PK sample will be recorded) . 
 Study visit Week 24 ( Day 169 ± 3 days ) – End-of-Part B visit  
The s ubject will take her daily dose at the usual time in the morning at home. 
The following tests and evaluations will be performed at week 24 Study Visit : 
- Weight  
- Assessment of endometriosis pain with the mB&B  scale (see APPENDIX B ) 
- Previous and concomitant treatments recording  
- AE recording  
- Physical examination  
- Vital signs (blood pressure and heart rate)  
- Gynecological examination, including the mB&B scale (see APPENDIX B ) clinical signs 
reporting ( pelvic tenderness and pelvic induration ) 
- TVUS  of uterus for measuring endometrium thickness and of ovaries for checking their 
normality  
- Urine pregnancy test  
- Contraception counselling  
- eDiary check for good completion  
- EHP -30 (see APPENDIX C ) and PGIC (see APPENDIX D ) questionnaires completion by [CONTACT_1560]  
- Post-dose PK samples (the approximate time of dose administration at home and time of taking 
of the PK sample will be recorded)  
- Blood samples for hae matology, coagulation parameters, c hemistry, l ipi[INVESTIGATOR_805], hormones  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 45 of 88 
 OBSEVA  CONFIDENTIAL  - Urinary protein dipstick  
- Endometrium biopsy , unless t he endometrium thickness in TVUS is ≤ 5 mm, in which case no 
endometrium biopsy will be necessary, as far as the screening biopsy has provided assessable 
results. Appropriate photo documentation of the endometrium thickness is mandatory.  
- BMD  assessed by [CONTACT_304727] A for femoral neck, hip and spi[INVESTIGATOR_050] . DXA can be performed ± [ADDRESS_372996] will stop the current study and continue in the extension study  
(see section 6.2.5) . 
Otherwise the subject will continue in the treatment -free follow -up period.  
6.2.4.  Follow -up period  without treatment – Study visits Week 28 ( Day 197 ± 3 days ), Week 
36 (Day 253 ± 3 days ) and Week 48 (Day 309 ± 3 days ) 
Up to week [ADDRESS_372997] on her eDiary:  
- Daily, at approximately the same time each evening , her IMP intake, pelvic pain, dyspareunia , 
difficulty in performing  daily activities, uterine bleeding and use of analgesic drug(s)  including 
dose; 
- Week ly, her dys chezia pain ; 
- 4-weekly , the patient ’s impression of severity . 
 Study visit  Week 28 ( Day 197 ± 3 days)  
The following tests and evaluations will be performed at Week 28 Study Visit : 
- Previous and concomitant treatments recording  
- AE recording  
- Vital signs (blood pressure and heart rate)  
- Blood samples for haematology, coagulation parameters, c hemistry, l ipi[INVESTIGATOR_805], hormones  
- Urinary protein dipstick  
- eDiary check for good completion  
- Urine pregnancy test   
- Contraception counselling  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 46 of 88 
 OBSEVA  CONFIDENTIAL  
 Study  visit Week 36 ( Day 253 ± 3 days)  
The following tests and evaluations will be performed at Week 36 Study Visit : 
- Weight  
- Assessment of endometriosis pain with the mB&B  scale (see APPENDIX B ) 
- Previous and concomitant treatments recording  
- AE recording  
- Physical examination  
- Vital signs (blood pressure and heart rate)  
- Gynecological examination, including  the mB&B  scale (see APPENDIX B ) clinical signs 
reporting ( pelvic tenderness and pelvic induration ) 
- Manual breast examination (by [CONTACT_23302])  
- TVUS for measuring endometrium thickness and of ovaries  for checking their normality  
- Urine pregnancy test  
- Contraception counselling  
- eDiary check  for good completion  
- EHP -30 (see APPENDIX C ) and PGIC (see APPENDIX D ) questionnaires completion by [CONTACT_1560]  
- Blood samples for haematology, coagulation parameters, c hemistry, l ipi[INVESTIGATOR_805], hormones  
- Urinary protein dipstick  
- Endometrium biopsy : will only be taken if no endometrial biopsy was obtained at week 24 or if 
diagnosis at week 24 was different from  “benign endometrium”   
 Study visit Week 48  (Day 309 ± 3 days) –  End of Follow -up visit 
The follo wing evaluation will be performed at Week 48 Study Visit : 
- BMD assessed by [CONTACT_304726], hip and spi[INVESTIGATOR_050] . DXA can be performed ±  [ADDRESS_372998] on 
BMD  
- Completion of the eCRF  exit form  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 47 of 88 
 OBSEVA  CONFIDENTIAL  6.2.5.  Planned extension of the study  
At the end of the treatment period (end of Part B) , the subject will be offered the opportunity to continue 
on active treatment for [ADDRESS_372999]’s assessment of  pelvic pain will be collected daily  via the eDiary  using a NRS and a VRS . 
NRS : The subject will be asked to rate her  worst endometriosis related pelvic pain in the last 24 hours 
on a 0–[ADDRESS_373000] pelvic pain imaginable.  
VRS : The subject will be asked to ch oose the category that best describes her  endometriosis related 
pelvic pain or discomfort in the last 24 hours : 
[ADDRESS_373001] 24 
hours  on a 0 –[ADDRESS_373002] will answer in the eDiary a two -item questionnaire assessing the incidence and amount of 
uterine/vaginal bleeding in the last 24 hours. The amount of uterine  bleeding will be assessed using the 
following VRS : 
1 - Spotting  A light amount of bleeding noted, no protection or panty shield only  
2 - Light  1–2 regular tampons or pads required in 24 hours   
3 - Medium  3–[ADDRESS_373003] eDiary will include daily selection -boxes for ibuprofen (provided by [CONTACT_3725]) , 
acetaminophen/ paracetamol  (provided by [CONTACT_3725])  or other . The subject will be asked to reco rd the number 
of tablets taken and t o confirm if t he reason for use is her endometriosis related pain.   
If the subject takes another pain medication and/or uses provided analgesics for pain other than her 
endometriosis related pain, she will be asked to record the details in a Pain Medication paper diary and 
bring this to her next site visit so that the details can be recorded in the eCRF.  
6.3.5.  Dyspareunia  (pain associated with sexual intercourse)  
The subject will be asked daily about d yspareunia via the eDiary  using a VR S and a NRS : 
VRS:  The subject will be asked to rate how her endometriosis related pain interfered with any sexual 
intercourse in the last 24 hours : 
 Not applicable : I was not sexually active  for reasons other than my endometriosis or 
did not have sexual intercourse.  
0  No discomfort during sexual intercourse . 
1  I was able to tolerate the discomfort during sexual intercourse.  
2  Intercourse was interrupted due to pain.  
3  I avoided sexual intercourse because of pain .  
NRS:  If subject reported she had pain during intercourse,  the subject will be asked to rate her worst 
endometriosis related pain experienced during or after sexual intercourse  in the last 24 hours  on a 0 –[ADDRESS_373004] pain imaginable.  
6.3.6.  Dyschezia  (pain associated with defecation)  
Dyschezia will be assessed weekly via the eDiary and will be scored by [CONTACT_48681] a 0–[ADDRESS_373005] will complete  in add ition two questionnaires  in the eDiary : EHP -30 and PGIC  (see APPENDIX 
C and APPENDIX D) . EHP -[ADDRESS_373006] will answer  in the eDiary an additional question to describe  the severity of her endometriosis 
condition over the preceding 4-week  period, with following possible answers: no symptoms, very mild, 
mild, moderate, severe. This question will be asked  every [ADDRESS_373007] using  the m B&B  scale (see APPENDIX B ) provided as 
paper questionnaire at screening visit  and Week s 12, 24 and 36 visits . This paper questionnaire will be 
kept as source data and corresponding scores recorded in eCRF  by [CONTACT_737].  
On the same visits, a gynecological assessment including the assessment of the  two clinical signs of the 
B&B - pelvic tenderness and pelvic induration  (see APPENDIX B ) - will be evaluated . Corresponding 
scores will be recorded in subject source data and in the eCRF by [CONTACT_941] I nvestigator.  
6.4. SAFETY OBSERVATIONS AND MEASUREMENTS  
6.4.1.  Adverse Events  
AE data will be col lected continuously during the study  as described in Section 8.  
AE data will be obtained at scheduled study visits based on physical examin ation, vital signs and  
biological laboratory assessments (see flowchart in APPENDIX A ). In addition, subjects will report 
AEs spontaneously and/or through questioning.  
Complete appropriate data on all AEs experienced for the duration of the reporting period, as d efined in 
section 8, will be reported on an ongoing basis in the AE pages of the eCRF . 
A complete physical examination, i.e. weight, examination of organ systems, including thyroid gland, 
lungs, heart, abdomen, liver, kidneys and peripheral pulses (by [CONTACT_304728], auscultation or percussion), 
eyes, ears, nose, throat and skin (by [CONTACT_122317]) and neurological reflexes will be performed at 
Screening , on Day [ADDRESS_373008] examination (by 
[CONTACT_23302]) will  be performed at Screening and W eek 36. Results of the examinations will be recorded 
on source subject  data file  and in the eCRF . Medical conditions present at screening that do worsen in 
severity and/or frequency during the study will be reported as AEs i n the corresponding eCRF page.  
6.4.2.  Vital signs  
Blood pressure (BP) and heart rate will be measured in sitting position at each monthly visit from the 
screening  visit to the Week 36 visit . In case of abnormal vital signs (i.e. BP ≥ 150/100 mmHg or ≤ 90/50 
mmHg and/or heart rate ≥ 100 bpm or ≤ 40 bpm) and if abnormality was not pre -existing, a repeat 
assessment after [ADDRESS_373009] systematically 
be reported by [CONTACT_941] I nvestigator in the eCRF  AE page. The Investigator is to provide a diagnosis rather 
than reporting of individual vital signs parameters whenever possible.  
6.4.3.  Trans vaginal ultrasound and endometrial biopsies  
Endometrial thickness , uterus volume and abnormality (fibroids, adenomyosis, etc…)  and left/right 
ovary abnormality status will be assessed by [CONTACT_304729] , at week s 12, [ADDRESS_373010]  and kept as source data. 
Results of the examinatio n will be recorded on source data forms and in the eCRF.  
Endometrial biopsies will be performed for histological assessment during screening , at week s 12 and 
24. At week 36, endometrial biopsy will only be taken i f no endometrial biopsy was obtained at week 
24 or  diagnosis at week 24 was different from “benign endometrium”  . Endometrial biopsy samples will 
be performed with the Pi[INVESTIGATOR_304686]® ( APPENDIX E) , as it will be described in the manual 
provided by [CONTACT_2237]. Endometrial biopsies will be centrally  assessed by [CONTACT_304730].  
If at week 12 and week 24 , the endometrium thickness in TVUS is ≤ 5 mm, no endometrium biopsy will 
be necessary, as far as the screening biopsy has provided assessable results. In this case the biopsy 
should be taken at week 36. However, if the week 24 biopsy result is available and indicated a benign 
endometrium then ano ther biops y is not required at week 36.  Appropriate photo documentation of the 
endometrium thickness is mandatory  and should be kept in the source documents at site . 
6.4.4.  Bone mineral density and DXA  
Bone mineral density  (BMD)  of femoral neck, hip and spi[INVESTIGATOR_304687], week s 
12, [ADDRESS_373011] withdrawal criteria based on BMD 
will be provided in a specific imaging manual , which will be provided to the Investigator . The DXA 
scans will be transferred to a central reading unit who will assess the BMD blind ed to treatment group.  
6.4.5.  Laboratory parameters  
Haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_304688] (serum levels of E2, 
progesterone [P4] and LH) will be assessed from  blood samples taken at screening, Day 1 and weeks 4, 
8, 12, 16, 20, 24, 28 and 36. Serum levels of the anti -müllerian hormone (AMH) will be assessed on 
Day 1  and serum levels of the sex hormone -binding globulin (SHBG) will be assessed on Day 1 and 
weeks 1 2 and 24. Blood samples will be analy zed by [CONTACT_2237] . Details of blood sampling 
process, sample handling and shipment are described separately in a laboratory manual provided by [CONTACT_19979]. Central laboratory reference ranges will  be filed in the investigator site file and in the 
trial master file. All laboratory results except E2, AMH, SHBG, P4  and LH levels will be assessed by 
[CONTACT_737]/sub -investigator and clinically significant abnormalities compared to screening/baselin e 
status will be reported as AEs in the eCRF . E2, AMH, SHBG, P4  and LH levels will not be 
communicated to keep the operational team and the sites blinded to treatment administration.  
The laboratory parameters are listed in  APPENDIX F . 
6.5. OBE2109 AND KP [ADDRESS_373012] on BMD will be recorded in the eCRF.  
The use of provided analges ics for endometriosis related pain will be recorded solely in the eDiary.  
6.6.1.  Permitted Medicines  
Analgesics:  
Subject s will be required to restrict  if possible  the use of analgesic to ibuprofen or 
acetaminophen/ paracetamol for the duration of the study , from the screening to the Week [ADDRESS_373013] doses of i buprofen and acetaminophen /paracetamol will be provided free of charge to the 
subject. The subject eDiary will include selection -boxes for ibuprofen, acetaminophen/ paracetamol or 
other , including  dosage . The analgesics provided will be used only as rescu e medication; no prophylactic 
use of analgesics is allowed during the whole study.  
Contraceptive use : 
For subjects of childbearing potential and requiring contraception, non- hormonal contraception is 
required from beginning of screening period until end of treatment . Two forms of non- hormonal 
contraception will be required e.g. condom with  spermicide. Suit able condoms with spermicide will be 
provided free of charge to subjects  over the duration of the study . 
After the end of treatment period (end of week 24) until the end of follow -up period, no contraception 
is required. For subject s wanting a contraceptiv e method, a single form of non- hormonal contraception  
is sufficient .  
Hormonal contraception is prohibited from beginning of screening period until end of week [ADDRESS_373014] s taking drugs metabolised by [CONTACT_097]3A4 experience a ttenuation of their effects and should 
consider a dose adjustment of the CYP3A4 substrate or discontinuation of OBE2109 as appropriate.  
Any medications other than thos e excluded by [CONTACT_760]  (see section 5.2.2 or 6.6.2 ), which are 
considered necessa ry for the subject’ s welfare and/or which will not inte rfere with the study medication , 
may be given at the discretion of the I nvestigator.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 52 of 88 
 OBSEVA  CONFIDENTIAL  6.6.2.  Prohibited Medicines  
Medication listed in exclusion criteria (see Section 5.2.2) will be prohibited up to week 36.  
To consider a subject who is currently taking any prohibited therapi[INVESTIGATOR_304689], the I nvestigator must e nsure  that the subject has sufficient washout time prior to enrolling the 
subject (see Section 5.2.2).  
Substrates of cytoch rome P450 2C8 (CYP2C8)  (e.g. montelukast, repaglinide ) and of organic anion 
transporter 3 (OAT3) (e.g. benzylpenicillin, sitagliptin, ciprofloxacin, pravastatin, rosuvastatin)  are 
prohibited during the treatment period only.  
When a prohibited medication or treatment is necessary for the subject’s well -being, the sponsor must 
be notified and possible alternatives are to be discussed before administration of the prohibited 
medication or treatment whenever possible.  
6.6.3.  Non-Drug Therapi[INVESTIGATOR_149947].  
6.7. SUBJECT  COMPLETION AND WITHDRAWAL  
6.7.1.  Subject Completion  
A subject will be considered as a “completer” when she has completed all study procedures at visit 
Week [ADDRESS_373015] completion 
(see APPENDIX A).  
Subjects who did not receive the study drug will be withdrawn from the study and no further study 
procedures will be performed. The eCR F exit form should be completed.  
6.7.2.  Subject Withdrawal from Study  
Subjects will be informed that they have the right to withdraw from the study at any time, without 
prejudice to their medical care, and that the y are not obliged to state the  reason (s). Any withdrawal must 
be fully documented in the eCRF  exit form and should be followed up by [CONTACT_941] I nvestigator.   
The Investigator may withdraw a subject at any time if this is considered to be in the subject’s best 
interest .  
In addition, the sponsor could make  a decision to temporarily or permanently discontinue the study for 
safety, ethical, compliance or other reasons.  In this case, the subject’s participation may be ended 
prematurely without asking for her  consent . 
Subjects discontinuing participation in the study between Day [ADDRESS_373016] may be discontinued for the following reasons : 
- Lack of Efficacy : Investigator ’s judgment only. If subject’s opi[INVESTIGATOR_154490], check s ubject’s 
Request. Explain in the comment section of the eCRF Exit Form. 
- Adverse Event : Includes clinically significant new or worsening existing condition as judged 
by [CONTACT_941] I nvestigator. Document in the AE form. 
- Subject ’s Request:  Consent withdrawal, subject moved, schedule conflicts, etc. Specify the 
reason in the comment section of the eCRF  Exit Form.  
- Protocol Violation:  Major protocol violation which may  affect the subject’s safety . Specify the 
protocol violation in the comment section of the eCRF  Exit Form. 
- Lost to Follow -up: Document with two phone calls and a certified letter requesting return receipt 
without response. Document in the comment section of the eCRF  Exit Form . 
- Pregnancy:  Subjects  that have been exposed to study treatment  and who become pregnant 
during the treatment period will be immediately withdrawn from treatment. 
Pregnancies that have been exposed to study treatment  and occurred up to  
week [ADDRESS_373017] be r eported with the Pregnancy Surveillance 
Form (see section 8.6).  
- Other:  Specify in the Comments section in the eCRF  Exit Form. This reason should 
only be used if the reason for discontinuation is not better accounted for by 
[CONTACT_304731].  
Subjects who have an elevation of hepatic enzymes suspi[INVESTIGATOR_304690] ( FDA)  guidance on drug -induced liver injury ( 26), i.e. LFT 
increase > [ADDRESS_373018] associated with increased bilirubin > [ADDRESS_373019],  will be immediately withdrawn from 
treatment and followed up to return to normal of hepatic parameters.  
All subjects withdrawn from treatmen t will enter – if appropriate – a 24-week follow -up period without 
treatment and continue daily eDiary recording  up to Week [ADDRESS_373020] S 
The term “Investigational Medicinal Product” (IMP) will refer to either the ObsEva  investigational drug 
or the placebo.  
 Investigational product  Placebo  
International nonproprietary 
name  (INN)  NA NA 
Name [CONTACT_304766]2109 NA 
Form  Film -coated tablet  Film -coated t ablet  
Streng th 50mg , 75mg  and 100mg placebo  
Dose or concentration  of 
active treatment  50mg, 75mg, 100mg 
and 200mg 0mg 
Route of administration  Oral 
Frequency of 
administration  Once daily for up to 24 weeks  
Manufacturer (Name [CONTACT_2758])  Catalent Pharma Solutions  
Steinbeisstrasse 1 -2 
D-[ZIP_CODE] Schorndorf,  
[LOCATION_013]  
Packaging (primary and 
secondary)  PVC/Al blister  with 7 tablets 
per blister , blister in two 
different colors (colored Al 
foil) for blinding purpose  
Aluminum pouch PVC/Al blister  with 7 tablets 
per blister , blister in two 
different colors  (colored Al 
foil) for blinding purpose  
Aluminum pouch 
Storage Requirements  As indicated on the study drug 
kit label  As indicated on the study drug kit label  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 55 of 88 
 OBSEVA  CONFIDENTIAL  7.2. DOSAGE AND ADMINISTRATION 
Investigational Medicinal Products  (IMPs)  
OBE2109 and placebo treatments will be supplied as film- coated t ablets for oral administration.  
The s ubject s will be given 3-monthly treatment packs . 
OBE2109 and placebo oral tablet treatment s will start on Day [ADDRESS_373021] ered once daily , up to about 24 weeks. The subjects will take 2 
tablets in the morning of  each day  as follows  : 
Treatment arm  Daily dose  Part A  
Day 1 to Week 12 Daily dose Part  B 
Week 12 to Week 24 
 Active tablet Placebo  tablet Active tablet Placebo tablet 
50 mg 1 × 50 mg 1 × placebo  1 × 50 mg 1 × placebo  
75 mg 1 × 75 mg 1 × placebo  1 × 75 mg 1 × placebo  
100 mg 1 × 100 mg 1 × placebo  1 × 100 mg 1 × placebo  
200 mg 2 × 100 mg None  2 × 100 mg None  
Titrated arm 1 × 75 mg 1 × placebo  Titrated dose*  1 × placebo  
Placebo /100 mg None  2 × placebo  1 × 100 mg 1 × placebo  
* Dose titrated after 12 weeks based on the mean E2 levels analyzed at weeks 4 and 8 as follows:  
• If E2 < 20 pg/mL then reduce the dose to 50 mg daily  
• If E2 > 50 pg/mL then increase the dose to 100 mg daily  
• If 20 ≤ E2 ≤ 50 pg/m L then dose remains at 75 mg per day  
7.3. PACKAGING AND LABELL ING  
Study drug will be provided by [CONTACT_456]  (or delegate)  as 3-monthly  kits. Each 3-monthly kit will 
contain 13 Aluminum (Al) pouche s containing two PVC/Al blister s of two different colors  (colored Al 
foil), i.e. sufficient to cover treatment for  [ADDRESS_373022] . 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 56 of 88 
 OBSEVA  CONFIDENTIAL  Part A – 3 -monthly treatment: 13 pouches/ 3-monthly kit – 26  blisters  (13 blisters of each color) – 
7 tablets/blister .
 
 
Part B – 3-monthly treatment: 13 pouches/ 3-monthly kit – 26 blister s (13 blister s of each color ) – 
7 tablets/blister.  
 
On Day [ADDRESS_373023] will be given one 3- monthly kit for a total of 13  weeks (i.e. 
including one extra week to cover  the allowed time window for visit scheduling) . 
Each day, from Day [ADDRESS_373024] in accordance 
with applicable local regulations , the recommendations of GMP guideline (Annex 13) and FDA [ADDRESS_373025] the following items:  
• Protocol number  
• Kit n umber  
• Batch number  
• Storage conditions  
• Sponsor name [CONTACT_3816]  
• Expi[INVESTIGATOR_5695] (for EU only)  
Label examples are filed in the study file at the Investigator’s site and in the trial master file.  
7.4. PREPARATION, HANDLING AND STORAGE  
The investigational site will store the IMP according to the specifications of the sponsor . The IMP 
storage conditions will be indicated on each pouch.  
The storage facility at site should be locked and temperature -controll ed. 
The storage temperature at the clinical site must be recorded by [CONTACT_2329] a minimum/maximum 
thermometer or electronically [ADDRESS_373026] or by a member of staff specifica lly authoriz ed by 
[CONTACT_737].  
Any deviations from the recommended storage conditions at the site should be immediately reported to 
the sponsor  (or delegate), and the IMP should not be used until authori zation has been given by [CONTACT_103]  (or delegate).  
7.5. IMP  ACCOUNTABILITY 
The Investigator is responsible for ensuring IMP accountability, including reconciliation and 
maintenance of drug records. 
• Upon receipt of the IMP, the Investigator  (or pharmacist) will check for accurate delivery and 
acknowledge receipt. A copy of acknow ledgement of receipt  will be retained in the investigator 
file. 
• The dispensing of the IMP will be carefully recorded on the appropriate drug account ability 
booklet  provided by [CONTACT_456]  (or delegate)  and an accurate accounting will be availabl e for 
verification by [CONTACT_304732].  
• IMP accountability records will include:  
o Confirmation of IMP delivery to the trial site  
15-OBE 2109- [ADDRESS_373027]  
o The return to the sponsor  (or delegate) or alternative disposition of unused IMP  
o Dates, quantities, batch numbers and kit  number s assigned to the subject . 
• The I nvestigator  should maintain records that adequately document:  
o The subject s were provided with the doses specified by [CONTACT_760]/amendment(s) . 
o All IMP provided were fully reconciled . 
Unused IMP must not be discarded or used for any purpose other than the present stu dy. IMP that has 
been partially dispensed to a subject  must not be re -dispensed to a different subject . 
The Study  monitor will periodically check  the IMP accountability booklet  and check all IMP  
dispensations and returns (both unused and used treatments ) during the entire study period and prior to 
making arrange ments for their return to the sponsor  (or delegate)  or authori zing their destruction by [CONTACT_304733] . 
7.6. ASSIGNMENT TO TREATM ENT GROUPS  
Prior to the start of the study, a randomization list and a treatment kit list will be generated by a 
designated statistician from the sponsor or delegate  to be transmitted to the assigned clinical packaging 
organization for labelling and to a fully integrated IWR S. 
Kit numbers assigned by [CONTACT_220137] S will start from K0001, K0002, K0003 etc. ( 5-characters) and will 
correspond to the kit number indicated on the label of the study drug.  
Complete blocks of treatment materials will be assigned to the investigational sites. However, the 
shipment of the treatment kits (as individual 3 -monthly kits) to each site  will be made on a n as-needed 
basis depending on the site screening rate.  
Subjects will be randomized to one of six treatment groups in a 1:1:1:1 :1:[ADDRESS_373028] inform the sponsor  immedi ately without revealing the 
code to the sponsor  study personnel and the complete Study Team. 
If a S erious Adverse Event (SAE)  is reported, the ObsEva (or delegate) Representative for 
Pharmacovigilance may unblind the treatment assignment for the affected  subject. When applicable, an 
expedited report will be sent to all I nvestigators in accordance with regulations.  
7.10. TREATMENT OF OVERDOS E AND MISUSE  
An overdose is defined as any dose (i.e. quantity of drug given per administration or per day) above the 
maximum dos age defin ed in the protocol.  
Misuse is the term used if more precise information is not available and additional information is needed 
to determine if there was a “medication error”, “drug abuse” or “overdose”.  
Any details of overdose  or misuse  must be recorded in the eCRF .  
Any case of overdose or misuse associated with an AE or a SAE must be reported  as per the instructions 
detailed in Section 8.2.  
The effects of an overdose of OBE 2109 are unknown, but single and repeated doses of up to 400 mg 
were shown to be safe in a Phase 1  single and multiple ascending dose study , and doses up to 200 mg 
daily for 3 months were safe in endometriosis subjects  (see Section 1.5) . 
7.11. OTHER SUPPLIES  TO BE USED IN THE STUDY 
A limited quantity (as per I nvestigator’s judgement) of standard doses of i buprofen and /or 
acetaminophen/ paracetamol will be given to the subject as standard rescue medication for endometriosis 
pain. Ibuprofen and acetaminophen/ paracetamol will be sourced by [CONTACT_304734].  
The subject will have  to record the intake of the analgesic rescue medication , including dose, in her 
eDiary. 
15-OBE 2109- [ADDRESS_373029]’s signature [CONTACT_43998]. Study site 
personnel will report any AE, whe ther observed by [CONTACT_941] I nvestigator or reported by [CONTACT_423] (see 
section 8.2.1, Eliciting Adverse Events).  
The safety profile of OBE 2109 will be assessed through th e recording, reporting and analys is of baseline 
medical conditions, AEs , physical examination findings , vital signs , laboratory tests , BMD  assessments. 
The reporting  period for AEs is described in section 8.5 . 
8.1. ADVERSE EVENTS  
8.1.1.  Definitions  
Adverse Event : 
An adverse event (AE) is defined as any  untoward medical occurrence in a clinical trial subject 
administered a n investigational  medicinal product (IMP) and which does not necessarily have a causal 
relationship with this treatment. It can therefore be any unfavourable sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not 
considered  related to the IMP. 
Events occurring prior to first IMP administration in the study are not considered AEs  per se, but an 
event that could be due to the disease or specific circumstances in which the subject has been placed 
(i.e. withdrawal of a previous drug to enter the study or “protocol -related”) . For monitoring purposes, 
any protocol -related event, as assessed by [CONTACT_941] I nvestigator, should be reported on an AE form or an SAE 
form, as appropriate.  
Severity : 
The severity of AEs must be assessed by [CONTACT_304735]. The 
term “severity” is used to describe the intensity of a specific event. This has to be distinguished from 
the term “serious”.  
Mild: The subject is aware of the event or symptom, but the event or sympto m is 
easily tolerated (e.g. no reduction in daily activities is required).  
Moderate:  The subject experiences sufficient discomfort to interfere with or reduce her 
usual level of activity.  
Severe:  Significant impairment of functioning: the subject is unab le to carry out usual 
activities and/or the subject’s life is at risk from the event.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 61 of 88 
 OBSEVA  CONFIDENTIAL  Causality a ssessment : 
The causality assessment of an AE to the IMP  will be rated as follows by [CONTACT_737]:  
Not related:  There is no reasonable possibility of causal relationship between an AE and 
IMP.  
Related:  There is at least a reasonable possibility of a causal relationship between an 
AE and an IMP. This means that there are facts (evidence) or arguments to 
suggest a causal relationship.  
 
Unexpected Adverse Event : 
Any AE which is not consistent in specificity or severity with the current Investigator’s Brochure, 
including all amendments, is considered unexpected.  
Outcome : 
Outcome describes the status of the AE. The I nvestigator will provide information regarding the subject 
outcome of each AE, and the options include:  
 
Fatal  Termination of life as a result of an AE . 
Not recovered/not resolved  Subject has not recuperated or the AE has not improved . 
Recovering/resolving  Subject is recuperating or the AE is improving . 
Recovered/resolved  Subject has recuperated or the AE has resolved . 
Recovered with sequelae/resolved 
with sequelae AE has resolved, but the subject has symptoms or pathology . 
Unknown  Unknown, not observed, not recorded, or refused . 
Action taken regarding study drug : 
The Investigator will provide the action taken regarding study drug in response to each AE, and the 
options include:  
Dose not changed No change in the administration of study drug . 
Drug (study drug) interrupted Temporary interruption (termination) in the  administration of 
study drug . 
Drug (study drug) withdrawn Administration of study drug is terminated (no further  dosing) . 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 62 of 88 
 OBSEVA  CONFIDENTIAL  Unknown  Unknown, not observed, not recorded, or refused.  
 
8.1.2.  Abnormal l aboratory findings and other objective measurements  
Abnormal laboratory findings and other objective measurements (e.g. vital signs ) must be reported as 
an AE only if assessed by [CONTACT_941] I nvestigator as “clinically significant”  e.g. meet ing at least one of the 
following conditions:  
1. The abnormality suggests a disease and/or organ toxicity AND this abnormality was not present 
at the screening visit or is assessed as having evolved since the screening visit.  
2. The abnormality is a Serious Adverse Event . 
3. The abnormality results in discontinuation of the IMP . 
4. The abnormality requires medical intervention or concomitant therapy . 
The Investigator  must initial and date each laboratory report /eCRF  page and note directly on the 
report /eCRF  page  whether or not eac h out -of-range laboratory result is clinically significant.  The 
outcome of this assessment will be reported using an  AE or SAE form, as appropriate.  
When reporting an abnormal finding for laboratory parameters or other objective measurements on the 
AE page  of the eCRF , a clinical diagnosis should be recorded rather than the abnormal value itself, if 
available (for example, “anaemia” rather than “decreased red blood cell count”) . 
For all of these AEs, whether or not related to the treatment, the laboratory test(s) will be followed -up 
as appropriate.  
8.1.3.  Baseline Medical Conditions  
Medical conditions present at the initial study visit are defined as Baseline Medical Conditions. These 
medical conditions should be adequately documented on the “ medical history page of the eCRF ”. 
Baseline Medical Conditions that worsen in severity or frequency during the study should be recorded 
and reported as AEs. 
8.1.4.  Exacerbation of endometriosis  
In this protocol, symptoms and signs of exacerbation or worsening of endometriosis will us ually be 
captured in the context of efficacy assessment. Therefore, symptoms, exacerbation or worsening of 
endometriosis will NOT be considered as AEs nor captured on the AE page of the eCRF unless clinically 
significant AND not consistent with the anticip ated natural progression of the disease. Lack of efficacy 
of the study drug is NOT considered as an AE.  
8.1.5.  Adverse Events of Special Interest  
Not Applicable . 
15-OBE 2109- [ADDRESS_373030] and/or through questioning of the subject.  
To elicit AEs, questioning at each study visit should begin with simple non- leading questions. For 
example:  
• How have you felt since your last visit?  
• Have you had any health problems since you were here last?  
If a subject is seen by a physician not involved with the study in relation to an AE , the Investigator  
should make every effort to contact [CONTACT_3433] e treating physician in a timely manner in order to obtain all 
information necessary for the appropriate reporting of the event.  
8.2.2.  Recording of Adverse Events in the eCRF  
As the quality and precision of acquired AE data are critical, Investigator s should use  the AE definitions 
provided in the above sections and should follow  this guideline when completing the AE pages of the 
eCRF : 
• Whenever possible, recogni zed medical terms should be used to describe AEs rather than 
colloquialisms (for example, ‘influenza’ rather than ‘flu’), and abbreviations should be avoided  
in provided AE term . 
• AEs should be described using a specific clinical diagnosis, if this is availabl e, rather than a list 
of component signs or symptoms (for example, ‘congestive heart failure’ rather tha n ‘dyspnoea, 
rales and cyanosis ’).  
• However, signs and symptoms that are not linked (as "co- manifestations”) to an identified 
disease or syndrome, or for which an overall diagnosis is not available, should be reported as 
individual AEs  in separate eCRF  AE page(s) .  
• Provisional diagnosis (e.g. “suspected Myocardial Infarction”) are acceptable but should be 
followed up to a definite diagnosis , if finally av ailable.  
• AEs occurring secondary to other events (e.g. sequelae or complications) should be identified 
by [CONTACT_86187]. A primary AE, if clearly identifiable, generally represents the most accurate clinical term to record in the eCRF . The Investigator  should be invited to provide 
his/her opi[INVESTIGATOR_263904]. 
8.2.3.  Reporting of Adverse Events  
Complete and accurate data on all AEs experienced for the duration of the reporting period, as defined in section 8.5 , will be reported on an ongoing basis in the AE pages of the eCRF . 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 64 of 88 
 OBSEVA  CONFIDENTIAL  It is important that each AE report includes a description of the event, whether it is considered serious 
(and if so the cri terion satisfied ), its duration (onset and resolution dates), its severity, its relationship to 
the IMP(s) , any other potential causality factors, any  treatment given or other action taken (including 
dose modification or discontinuation of the IMP ) and its  outcome. 
8.3. SERIOUS ADVERSE EVENTS  
8.3.1.  Definitions  
A Serious Adverse Event (SAE) is defined as a ny untoward medical occurrence or effect that at any 
dose:  
• results in death , 
i.e. the AE causes or contributes to the death.  
• is life -threatening , 
i.e. the AE places the subject at immediate risk of death; it does not refer to AE which 
hypothetically might have caused death if it were more severe.  
• requires inpatient hospi[INVESTIGATOR_1081] , 
i.e. the AE requires at least an overnight admission or prolongs a hospi[INVESTIGATOR_304691]. Hospi[INVESTIGATOR_304692], for social reasons, for any elective surgery (i.e. plastic surgery) or for normal disease management (including treatmen t adjustment) are NOT to be considered as SAE according to this criterion .. 
• results in persistent or significant disability / incapacity , 
i.e. the AE resulted in a substantial disruption of the subject’s ability to conduct normal 
activities.  
• is a congenita l anomaly / birth defect , 
i.e. an adverse outcome in a child or fetus  of a subject exposed to the IMP  before conception  or 
during pregnancy. 
• is an important medical event , i.e. is medically significant  ; 
Medical and scientific judgment should be exercised in deciding whether an AE  is serious in 
other situation. Important medical events that may not be immediately life -threatening or result 
in death or hospi[INVESTIGATOR_304693] r equire intervention to prevent 
one of the other outcomes listed in the definition above should also be considered serious. Examples of such events are intensive treatment in an emergency room, or at home for allergic 
bronchos pasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_18543], or 
development of drug dependency or drug abuse.  
15-OBE 2109- [ADDRESS_373031] notify  VOISIN CONSULTING  (acting on behalf of ObsEva  
Pharmacovigilance ) WITHIN 24 HOURS  of awareness of a new SAE or of new information on a 
previously reported SAE (=  follow -up). 
To do so, the Investigator  must complete a SAE report and any specific eCRF  pages if justified by [CONTACT_12695] e.g. AE, medical history, concomitant medication eCRF  pages and blinded and anonymized 
copi[INVESTIGATOR_304694], hospi[INVESTIGATOR_304695]/report, 
etc. ) , sign it and send it direct ly to Voisin Consulting  by e-mail using the dedicated e- mail address 
specified below : 
 Name/Title :  Voisin Consulting  / ObsEva  Pharmacovigilance  
 E-mail:    [EMAIL_5974]  
VOISIN CONSULTING  will notify ObsEva Pharmacovigilance within 1 working day after the receipt 
of the SAE form report or follow -up information, using the same reporting forms. 
The SAE follow -up observation period, for the concerned subjects , will be jointly decided by [CONTACT_304736]- investigator s (in case of Investigator ’s absence) and the sponsor .  
In addition, the Investigator  must respond to any request for follow -up information or questions 
regarding the SAE the sponsor  may have , within  1 working day for urgent queries or 5 working days 
for normal queries . SAE will be followed until the Investigator  and ObsEva agree that the event is 
satisfactor ily documented and resolved/stabilized . 
For any new SAE, the following minimum information is required as initial notification:  
• Clear identification of the Investiga tor/Reporter with full contact [CONTACT_304737] , 
• Subject identification details (study number, site number, subject’s unique study identification 
number and date of birth ), 
• IMP(s) administration details (dose and dates) , 
• Diagnosis of the event (or a brief description of signs/symptoms/clinical course if the diagnosis 
is not available) and the date of onset,  
• Seriousness criteria, see 8.3.1, 
• Causal r elationship (Investigator ’s opi[INVESTIGATOR_1649]) of the event with the IMP (s) or with the trial 
procedure (e.g. the causality according to the Investigator  during screening ). 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 66 of 88 
 OBSEVA  CONFIDENTIAL  8.4. REPORTING TO THE IND EPENDENT ETHICS COMM ITTEES / 
INSTITUTIONAL REVIEW BOARDS  AND REGULATORY AUTHORITI ES 
The Investigator  must comply with any applicable requirements related to the reporting of SAEs 
involving the study  subjects to the IEC /IRB  that approved the study.  
ObsEva will comply with the applicable regulatory requirements related to the expedited reporting  of 
suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) to the regulatory authorities  (e.g. Health 
Authority, Central Ethics Committee , Central IRB) . In the US, t he sponsor will be responsible, through 
their US Agent, for notifying the FDA of any S[LOCATION_003]R , and the sponsor or designee is responsible for 
notifying the Central IRB ; in the European Union (EU), the sponsor or designee is responsible for 
notifying the European Medicines Agency, IEC, and Competent Authorities. In regions/countries other 
than the US/EU, reporting of events to IECs or local authorities will be performed by [CONTACT_3786] /sponsor or designee and in accordance with local procedures/regulations.  
In accordance with ICH GCP guidelines, the sponsor  will inform the Investigator  of “findings that could 
affect adversely the safety of subjects, impact the conduct of the trial or alter the IEC /IRB ’s 
approval/favourable opi[INVESTIGATOR_150831]” . In particular and in line with respect ive regulations , 
the sponsor  will inform the Investigator  of AEs that are both serious and unexpected (i.e. as per the  
OBE 2109 Investigator Brochure ) and are considered by [CONTACT_135125] s ponsor, to have a 
reasonably possibility of causal relationship between  the administered IMP and the AE  (i.e. S[LOCATION_003]R) . 
The Investigator  will keep copi[INVESTIGATOR_304696] ’s file. National regulations 
with regards to safety reports notifications to I nvestigator s will be taken into account.  
Unless clearly defined otherwise by [CONTACT_108103]- specific regulations, and duly documented, the 
responsible Investigator  will promptly notify the concerned IEC /IRB  of any safety reports provided by 
[CONTACT_304738][INVESTIGATOR_304697] . Only when specifically 
required by [CONTACT_19124], the sponsor  (or delegate) will provide appropriate s afety reports directly to the 
concerned IEC /IRB  and maintain records of these notifications.  
8.5. REPORTING PERIOD 
Adverse Events (AEs) are collected on an ongoing basis from the day of signed informed consent . All 
new AEs and updates on all ongoing AEs or AEs with an unknown outcome, must be recorded up to 
week 36, with the exception of a n AE related to BMD loss which will be reported up to week 48. 
Protocol -related events occurring during the screening period (i.e between ICF signature [CONTACT_304767] 1 
visit)  must be recorded in the eCRFs using the AE form (and  SAE form if appropriate) until the date the 
subject is determined to be a screening failure. Beyond that date, only serious or medically relevant 
protocol -related  events will be followed -up. 
A last batch of queries will be sent after last study visit if remaining ongoing/unknown outcomes of  
reported AEs are pending. After the last batch of queries with all collected data have been fully 
processed, eCRF s and database will no longer be updated. Only SAEs and medically relevant 
ongoing/unknown outcome AEs  will be followed- up until resolution or sta bilization , under Voisin 
Consulting  responsibility.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 67 of 88 
 OBSEVA  CONFIDENTIAL  8.6. PREGNANCY AND IN UTE RO DRUG EXPOSURE  
Only pregnancies considered related to study treatment by [CONTACT_737]  (i.e. resulting from a drug 
interaction) are considere d as AEs.  
However , all pregnancies that are conceived up to week [ADDRESS_373032] be recorded using the Pregnancy 
Surveillance Form  (PSF)  – Part I  (History and Start of Pregnancy; PSF -part I), provided by [CONTACT_103]  (or delegate) at the beginning of the study.  
Initial reporting of pregnancies:  
Subjects who become pregnant during the study treatment period will be immediately withdrawn from 
the IMP  treatment.  
The Investigator  must notify the sponsor  in an expedited manner (same as SAE reporting) of any 
pregnancy occurring during the above -mentioned period, by [CONTACT_304739]-part I . 
This form should be sent to ObsEva’s  Representative for Pharmacovigilance as per the same procedures 
and timelines described for expedited AE reporting in section 8.3.2. This form should be accompanied, 
as needed, by [CONTACT_304740][INVESTIGATOR_304698], Previous and Concomitant Therapy and the Exit 
Form.  
Follow -up of pregnancies:  
The Investigator  must actively follow -up, document and report to ObsEva’s Representative for 
Pharmacovigilance the progress by [CONTACT_248879] -monthly updates up to the final outcome of the pregnancy  
using the Pregnancy Surveilla nce Form – Part II : (Course of Pregnancy; PSF -part II). If the subject 
can no longer be reached (lost to follow -up), documentation of the non- response/contact [CONTACT_304741] a letter (certified with return receipt) are required.  
Pregnancy outcome s are not recorded in the e CRF unless considered AEs.  
Pregnancy outcomes  must be reported to ObsEva ’s Representative for Pharmacovigilance by 
[CONTACT_304742] – Part III : (Course and Outcome of Pregnancy; PSF -
part III). Timelines vary according to the nature of the pregnancy outcome:  
- For normal outcomes, ObsEva’s Representative for Pharmacovigilance should be 
 notified within 45 days of birth/delivery. 
- For abnormal outcomes, the fully completed form must be sent to ObsEva’s 
 Representative for Pharmacovigilance according to the same procedures and timelines 
 described for expedited AE reporting in section 8.3.2. (within 24 hours of awareness of this 
 outcome). A SAE Report form must be completed when the subject sustains an event while 
 PSF- part III must be completed when the child/foetus sustains an event . Abnormal outcomes 
 are defined as:  
• Abnormality of the baby (birth defect): in this case , a SAE form for t he child should be 
complete d in addition to the PSF- III. 
• Abnormality for the pregnancy (spontaneous abortion, stillbirth) or abnormality for the 
birth itself which could fulfil criteria of SAEs  (e.g. prolongation of hospi[INVESTIGATOR_304699] 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 68 of 88 
 OBSEVA  CONFIDENTIAL  to caesarean section  complications): in this case please complete in supplement to the 
PSF- III a SAE form for the mother.  
9. DATA ANALYSIS AND ST ATISTICS  
9.1. TEST OF HYPOTHESES  
The primary objective of the study is to assess the efficacy of a range of oral doses of OBE2109 versus 
placebo, in reducing overall  pelvic pain in subjects with moderate  to severe endometriosis pain . The 
corresponding primary endpoint is a 30% or greater reduction from baseline to week 12 in the mean 
overall pelvic pain score defined as the mean of daily pain scores reported during the preceding 4- week 
period assessed on a  0–3 VRS for pelvic pain . 
The primary objective will be assessed by [CONTACT_304743]:  
Null hypothesis (H0): There is no difference in the proportion of subjects meeting the primary endpoint 
for the active treatment group compared to placebo.  
H0: p ( active) = p ( placebo ) 
Alternative hypothesis (H1): There is a difference in the proportion of subjects meeting the primary 
endpoint for the active treatment group compared to placebo.  
H1: p ( active) ≠ p ( placebo ) 
Where p is the proportion of subjects with a reduction equal to or above 30% from baseline to week 12 in the mean overall pelvic pain score reported during the preceding 4- week period . 
Each  comparison will be carried out at the two- sided 5% level of statistical significance. No adjustment 
will be made for the multiple active versus placebo group comparisons (four in total: 50mg versus 
placebo, 75mg vers us placebo, 100mg versus placebo and 200mg versus placebo) with the 
understanding that this increase the overall type I error rate of the study.  
In addition, an overall test for dose response will be conducted using all treatment arms. The coefficients for this contrast will be defined as suming a linear response on a log (dose+1) scale.  
9.2. SAMPLE SIZE 
The planned sample size for this study is 55 subjects per treatment arm (330 subjects in total). The sample size calculation is based on pairwise comparisons for each active dose versus placebo. A two -
sided type I error of 0.05, not adjusted for multiple c omparisons against placebo, will be used for this 
exploratory study. Fifty five ( 55) subjects per arm will provide a power of 90% assuming a placebo 
response rate of 45.5% and an active treatment response rate of 76.9% (based on data from Kissei’s Phase 2 study KLH1202) . 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 69 of 88 
 OBSEVA  CONFIDENTIAL  9.3. RANDOMI ZATION 
Randomization will be performed via a centralized IWR S. Subjects will be randomized on Day 1 to one 
of six treatment groups in a 1:1:1:1 :1:1 ratio for OBE 2109 placebo/ 100mg  group, OBE2109 50mg fixed-
dose group, OBE2109 75mg fi xed-dose group, OBE2109 100mg fixed- dose group, OBE2109 200mg 
fixed -dose group, O BE2109 75mg titrated -dose group,  stratified by [CONTACT_3725] . 
Subjects will be randomized into blocks of a pre -determined length, with complete blocks being 
assigned to the investigational sites. 
9.4. ANALYSIS SETS  
The following data sets will be used for the statistical analysis:  
1. Safety Set : All randomized subjects who received at least one dose of double- blind study drug 
irrespective of the treatment received. Subjects will be analyzed according to treatment 
received.  
2. Full Analysis Set (FAS):  All randomized subjects who received at least one dose of double -
blind study drug irrespective of the treatment received. Subjects will be analyzed according to 
randomized treatment.  
3. Week 12 Per Protocol (PP) Set: All subjects in the FAS excluding those identified as major 
protocol violators up to Week 12.  
4. Week 24 Per Protocol (PP) Set: All subjects in the FAS excluding those identified as major 
protocol violators up to Wee k 24. 
5. Pharmacokinetic  (PK)  Set: all subjects who received active study medication  and had no 
major protocol deviations.  
Any pre -planned s ub-group analyses will be described in the statistical analysis plan ( SAP). 
9.5. DATA ANALYSIS  
More details of the proposed statistical analysis will be documented in the SAP , which will be written 
following finali zation of the protocol and prior to the  interim analysis of the Part A data.  
Analyses of Part B study data will be fully described in the  SAP.  
For continuous data and for ordered categorical data, if appropriate, the number of non- missing 
observations, mean, standard deviation, median, first and third quartiles, minimum and maximum will be calculated.  
For ordered categorical data and nominal data, absolute counts and relative frequencies (in %) will be 
calculated.   
Data for the 75mg group and 75mg titrated group will be combined for the analyses of the Part A data.  
All statistical hypothesis tests and confidence intervals will be two sided,  using a t ype I error rate of 
0.05. No adjustment for multiple comparisons will be used for this study. 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 70 of 88 
 OBSEVA  CONFIDENTIAL  Raw data will be listed.  
9.5.1.  Baseline Assessment  
Descriptive statistics will be performed on relevant screening and baseline data (i.e. data collected prior 
to the treatment administration) and on demographic characteristics for each treatment group and 
overall. There will be no formal comparison of base line data, that is, no statistical hypothesis testing.  
9.5.2.  Primary Efficacy Analysis  
Mean overall pelvic pain scores will be calculated separately for the V RS and NRS by [CONTACT_304744] 4 -week (28 day) periods and dividing by [CONTACT_304745] (i.e. nominally 28 days if no missing data). The baseline mean overall pelvic 
pain score will be calculated as the mean over the two  complete menstrual cycles  during screening, 
which may not be exactly 2 8 days  each . 
The percentage of subjects with a 30% or greater reduction from baseline to week 12 (i.e. during the 4 
weeks preceding week 12 time point) in the mean overall pelvic pain score will be summarized by [CONTACT_304746].  
The analysis of the primary endpoint will be conducted via a generalized linear model for binary data with repeated (correlated) measures, fitted using generalized estimating equations (a marginal  model), 
with the model including terms for treatment group, 4-week  period, baseline and the interactions 4-week  
period*treatment, 4- week  period *baseline.  
9.5.3.  Secondary Efficacy Analysis  
Mean overall pelvic pain scores will also be calculated separately for t he NRS in the same way as for 
the VRS . 
Mean pelvic pain scores on uterine bleeding days and non -uterine bleeding days will be calculated by 
[CONTACT_304747] (uterine bleeding days will be defined as those days on 
which the subject records any uterine bleeding  or spotting  in the subject eDiary) and dividing by [CONTACT_304748] . Both the total number of non- missing days in the 4 -week period 
(i.e. nominally 28 days if no missing data) and the number of non- missing uterine bleeding days/non -
uterine bleeding days will be considered.  
All secondary efficacy endpoints will be summarized by [CONTACT_304712], for each time point , including summaries or change from basel ine when applicable . The 
definition of baseline for each endpoint will be defined in the SAP. As with the primary analysis, 
individual active versus placebo arm comparisons will be made. In addition, an overall test for dose 
response will be cond ucted using all treatment arms.  
In general, between group comparisons for continuous endpoints will be analyzed via (repeated measures) analysis of (co) -variance (repeated measures mixed models) or Wilcoxon Rank Sum tests, 
subject to the underlying distribution of the data. Between group comparisons for binary endpoints will 
be analyzed via generalized linear models (with repeated measures) and chi -squared tests. Between -
group comparisons for count data ( e.g. number of days) will also be analyzed via generalized linear 
models (with repeated measures).   
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 71 of 88 
 OBSEVA  CONFIDENTIAL  It is not certain whether the  continuous  endpoints will be normally or log -normally distributed, and/or 
whether an absolute or proportional change i n endpoints will be observed. If deemed necessary , the data 
will be log transformed prior to the analysis. The subsequent results (mean differences and 
corresponding confidence intervals) will be back transformed and hence reported in terms of ratios of 
geometric means.  
Potential responder definitions for future studies will be explored . These are likely to incorporate use of 
rescue analgesics and reduction in difficulty of pain with daily activities,  in addition to pain. A responder 
threshold that  constitutes a meaningful reduction in symptomatology  will also be explored, potentially 
by [CONTACT_112863] a cumulative distribution and/or via an a nchor based method using the PGIC  and other 
appropriate endpoints and methods .  
9.5.4.  Safety analysis methodology 
The safety and tolerability profile will be assessed versus baseline conditions and differences between 
treatment groups and descriptive statistics will be produced, where applicable.  No formal hypothesis 
testing of safety data will be undertaken.  
A treatment -emergent analysis will be done for AEs. AEs will be tabulated by [CONTACT_304749]. Tabulations by [CONTACT_304750] -relatedness will also be made.  
Extent of exposure and compliance will be evaluated.  
The Safety Analysis Set shal l be used when summarizing safety data.  
9.5.5.  Pharmacokinetic analysis methodology  
PK Analysis will be performed by [CONTACT_304751]. The analyses have to be performed unblinded by 
[CONTACT_304752]. The analyst may be aware of the subject number, sampli ng time and dose 
group. For descriptive statistics of plasma concentrations mean (arithmetic and geometric), standard 
deviation, median, 1st and 3rd quartiles, minimum, maximum, coefficient of variation (CV%) and 
number  of observations  will be provided. Concentrations below the limit of quantification (LOQ) will 
be assigned a value of zero . 
9.5.6.  Pharmacodynamic analysis methodology  
Possible PK -PD relationships will be investigated graphically and through statistical modeling , whilst 
also exploring possible cov ariates.  
9.5.7.  Missing Data  
Summary statistics will be based primarily on non -missing values. For hypothesis tests , estimates and 
confidence intervals, missing values for continuous efficacy endpoints analyzed via likelihood methods 
(e.g. repeated measures mixed  models) will not be directly imputed as they are handled within the 
analysis itself, under the assumption that the model specification is correct and that the data is missing 
at random. In addition, missing values for endpoints analyzed via generalized es timating equations will 
not be directly imputed as they are handled under the assumption that  the model specification is correct 
and the data is missing completely at random. Sensitivity analyses may be conducted  to check  the 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 72 of 88 
 OBSEVA  CONFIDENTIAL  robustness of the analysis results under alternative assumptions with regards to missing data.  Further 
details on the handling of missing values, including rules applied to incomplete questionnaires 
(including incomplete diary entries) and any planned sensitivity analyses will be d efined in the SAP.  
9.6. STUDY SPECIFIC DATA ANALYSIS  
9.6.1.  Interim Analysis  
An un- blinded interim analysis of Part A data to assess efficacy and safety parameters will be performed 
by [CONTACT_304753] [ADDRESS_373033] completed the Part B treatment period (week 24), a complete analysis of Part A 
and Part B data will be performed. The results for the study parts A and B will be summarized and 
described in an integrated Clinical Study Report.  
A 24-week follow -up period without treatment is planned after Part B.  
An analysis will be performed after week [ADDRESS_373034] their 
origin in the Declaration of Helsinki ( 27), the ICH Harmoni zed Tripartite Guideline for GCP, and all 
applicable local regulatory requirements.  
10.1.1.  Informed Consent  
Before a subject can partic ipate in the study, she must give written informed consent. The informed 
consent process will be in accordance with ICH GCP, and local regulatory requirements.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 73 of 88 
 OBSEVA  CONFIDENTIAL  10.1.2.  Regulatory Authority Approval  
Before the study is initiated at a site, the sponsor  (or its deleg ate) will obtain approval to conduct the 
study from the appropriate regulatory authority in accordance with any applicable country -specific 
regulatory requirements.  
10.1.3.  Institutional Review Board/ Independent Ethics Committee Requirements  
Before initiation of the study at a given site , written approval of the protocol, ICF  and any information 
presented to potential subjects must be obtained from the appropriate Institutional Review Board or 
Independent Ethics Committee  (IRB/IEC) . If any ame ndments to any of these documents occur during 
the study, notification or written approval  as appropriate  must be obtained prior to their implementation. 
The Investigator  is responsible for ensuring that these actions occur.  
Where required by [CONTACT_276882], the sponsor  (or its delegate) is responsible for ensuring IEC /IRB  
approval of the study.  
10.1.4.  End of the study  
For administrative and safety reporting purposes the end of the study will be defined as the date of the 
final clinical database lock  after the last subject ha s completed Week [ADDRESS_373035] the study according to ICH GCP guidelines , the 
FDA Code of Regulation or the EU Clinical Trial Directive and applicable local laws and regulations.  
10.2.1.  Coordinating Investigator  
[INVESTIGATOR_304700], national level coordinating Investigator s may be appointed. Their 
responsibilities are outlined in a separate agreement with the sponsor . 
10.3. DATA MANAGEMENT  
The Investigator  or designee will be responsible for  recording study data in the eCRF  provided by [CONTACT_103] . It is the Investigator ’s responsibility to ensure the accuracy of the data entered in the e CRF s. 
The data will be entered into a validated database.  The sponsor  or delegate wi ll be responsible for data 
processing, in accordance with the sponsor  (or delegate) data management procedures. Database lock 
will occur once quality assurance procedures h ave been completed. The database wi ll not be locked 
before all data clarifications have been resolved and monitored and the decision on subject evaluation 
has been completed.  PDF files of the e CRF s will be sent to the Investigator  at the completion of the 
study. 
10.4. STUDY MONITORING  
The Investigator  must ensure that eCRF s are completed in a timely manner and must allow a sponsor  
representative ( e.g. CRA or study monitor) periodical access to subject records and all study- related 
15-OBE 2109- [ADDRESS_373036] source data verification.  
Upon study completion, the sponsor  representative ( e.g. CRA or s tudy monitor ) will visit the site to 
conduct a Study termination visit. This will involve collection of any outstanding documentation.  
10.5. REVIEW  COMMITTEE(S)  
10.5.1.  Data Monitoring Committe  (DM C) 
The DMC is a group of independent experts external to the study that, collectively, has experience in 
the management of subjects with endometriosis , and in the conduct and oversight of randomi zed clinical 
trials.  
Composition, responsibilities, rules for de cision and procedures of the DMC will be described in more 
details in the DMC charter.  
The DMC  will be responsible for : 
- safeguarding the i nterests of trial participants,  
- assessing the safety of the IMP during the trial (reviewing unblinded safety data and AEs and SAEs, 
on a regular basis, as per charter prepared for the study).  
The DMC  will provide advisory support to the Study Director, the trial team and any  other sponsor 
representative. The Study Director will be responsible for promptly reviewing the DMC  
recommendations and determine whether expedited reporting of any safety issues, amendments to the protocol or changes in study conduct are required.  
10.6. SUBJECT CONFIDENTIAL ITY 
The Investigator  and the CRA  (or study monitor) representing the sponsor  must e nsure that the subject’ s 
anonymity is maintained. I n the eCRF s or other documents submitted to the sponsor , the subject should 
not be identified by [CONTACT_304754], but by [CONTACT_304755]. If a subject ’s name [CONTACT_304768][INVESTIGATOR_304701] , the name ( except for initials)  must be obliterated and the 
assigned SIN  added to the documents.  
The Investigator  should keep a separate log of SINs , names, addresses, telephone numbers and hospi[INVESTIGATOR_281223] (if applicable) . Documen ts not for submission to the sponsor , such as signed ICF s, should be 
maintained in strict confiden tiality  by [CONTACT_737] . 
10.7. QUALITY ASSURANCE  
In compliance with ICH GCP and regulatory requirements, the sponsor , a third party acting on behalf 
of the sponsor , regulatory agencies or IRB/IECs may conduct quality assurance audits at any time during 
or following a study. The Investigator  must agree to allow auditors direct access to all study -related 
15-OBE 2109- [ADDRESS_373037] agree to allocate his or her time and the time of his or 
her study staff to the auditors in order to discuss findings and issues.  
10.8. STUDY OR SITE DISCONTINUATION 
The sponsor  may temporarily or permanently discontinue the study for safety, ethical, compliance or 
other  reasons. If this is necessary, the sponsor  will endeavour to provide advance notification to the site. 
If the site or study is suspended or discontinued, the Investigator  will be responsible for promptly 
informing the IEC /IRB .  
Where required by [CONTACT_56812], the sponsor  (or delegate) will be responsible for informing the 
IEC/IRB  of study or site discontinuation. In such cases, all study data and unused IMP must be returned 
to the sponsor . 
10.9. RETENTION OF ESSENTI AL STUDY DOCUMENTS  
Essential documents as defined by [CONTACT_304756](s), copi[INVESTIGATOR_304702] s, signed ICFs from all subjects who consented, hospi[INVESTIGATOR_1097], diary cards and 
other source documents,  IEC approvals and all related correspondence including approved documents, 
drug accountability records, study correspondence and a list of the subjects’ names and addresses.  
The Investigator  must retain copi[INVESTIGATOR_304703].  
The Investigator  will inform the sponsor  of the storage location of the essential documents, and must 
contact [CONTACT_304757]. The Investigator  should take measur es to 
prevent accidental or premature destruction of these documents.  
  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 76 of 88 
 OBSEVA  CONFIDENTIAL  11. APPENDICES  
 
 SCHEDULE OF STUDY ASSESSMENT S ...................................................................... 77 
 MODIFIED BIBEROGLU &  BEHRMAN SYMPTOM SEVE RITY SCALE*  ....................... 78 
 ENDOMETRIOSIS HEALTH  PROFILE QUESTIONNAIR E (EHP -30) .............................. 79 
 PATIENT GLOBAL IMPRESSION OF CHANGE  ........................................................... 83 
 PI[INVESTIGATOR_304675]®  ............................................................................................. [ADDRESS_373038]  ...................................................................................................... 87 

15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 77 of 88 
 OBSEVA  CONFIDENTIAL  
 SCHEDULE OF STUDY ASSESSMENTS  
Timing1 Screening  Part A  Part B  Follow -Up 
 11±5 
weeks  Day 1  W4 W8 W12 W16 W20 W24 W28 W36 W48 
Informed Consent  X           
Demography, height, weight, 
medical history  X       X6  X6  
Previous/concomitant medication  X X X X X X X X X X X7 
Inclusion -Exclusion criteria  X X          
Physical examination  X X   X   X  X  
Vital signs  X X X X X X X X X X  
Gynecological examination and 
mB&B  X    X   X  X  
Breast manual examination  X         X  
Pap test  X           
Endometrium TVUS  X    X   X  X  
Endometrial biopsy  X    X2   X2  X3   
Clinical laboratory & urinary 
protein dipstick  X X X X X X X X X X  
Blood sample for PK 4  X4 X4 X X X4 X X    
OBE2109/Placebo taken daily       
Subject eDiary completion 
training/ check5 X X X X X X X X X X  
EHP-[ADDRESS_373039] at the end of the defined period (i.e. week 4 visit should be scheduled at the end of week 4, week 
8 visit should be scheduled at the end of week 8, etc.).  Post -baseline visits dates are calculated from Day 1 visit date.     
2  If endometrium thickness in TVUS is ≤ 5 mm, no endometrium biopsy will be necessary, as far as the screening biopsy has provided 
assessable results.  
3 If diagnosis at week 24 was different from “benign endometrium”  or if no endometrial biopsy was obtained  at week [ADDRESS_373040] of patient’s impression of severity.  
[ADDRESS_373041] in eCRF only if related to BMD (any m edications with potential impact on BMD or any AEs related 
to BMD loss).  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 78 of 88 
 OBSEVA  CONFIDENTIAL  
 MODIFIED BIBEROGLU & BEHRMAN  SYMPTOM
 SEVERITY SCALE*  
 
A. Dysmenorrhea  
None  0 = No symptoms  
Mild  1 = Some loss of ability to work or carry out normal activities  
Moderate  2 = Unable to work or carry out normal daily activities for part of 1 or more days 
and/or moderately decreased work efficiency  
Severe  3 = Unable to work or carry out normal daily activities for 1 or more full days and/or 
significantly decreased work efficiency  
 
B. Deep Dyspareunia  
None  0 = No symptoms  
Mild  1 = Tolerated discomfort during intercou rse 
Moderate  2 = Interference of usual frequency of sexual intercourse due to pain  
Severe  3 = Avoids, or wishes to avoid, intercourse because of pain  
 
C. Non Menstrual P elvic Pain  
None  0 = No symptoms  
Mild  1 = Occasional pelvic discomfort  
Moderate  2 = Noticeable discomfort for most of cycle  
Severe  3 = Pain persistent during cycle other than during menstruation  
 
 
D. Pelvic Tenderness  (assessed by [CONTACT_304758])  
None  0 = No findings  
Mild  1 = Minimal tenderness on palpation  
Moderate  2 = Moderate tenderness on palpation  
Severe  3 = Exam limited due to tenderness  
 
E. Induration  (assessed by [CONTACT_099] ) 
None  0 = No findings  
Mild  1 = Uterus freely mobile, minimal induration in the cul- de-sac 
Moderate  2 = Significant induration in the cul- de-sac, restricted uterine mobility  
Severe  3 = Nodular adnexa and cul -de-sac, uterus fixed  
 
Composite Pelvic  Pain and Physical S ign Score (A + B + C + D + E)  
None   0 
Mild   1 - 2 
Moderate   3 - 5  
Severe   6 - 10 
Very Severe   11 – 15 
 * based on Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short 
term and long term effectiveness. Am J Obstet Gynecol. 1981;139:645.    Total Pelvic Pain Score (A + B + C)  
None   0 
Mild   1 - 3 
Moderate  4 - 6  
Severe   7 - 9 
Total Physical Sign Score (D + E)  
None   0 
Mild   1 - 2 
Moderate  3 - 4  
Severe   5 - 6 
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 79 of 88 
 OBSEVA  CONFIDENTIAL  
 ENDOMETRIOSIS HEALTH  PROFILE QUESTIONNAIRE  
(EHP -30) 
 
PART  1: CORE  QUESTIONNAIRE  
DURING THE LAST [ADDRESS_373042] YOU... 
 Never  Rarely  Sometimes  Often  Always  
1. Been unable to go to social events 
because of the pain?        
2. Been unable to do jobs around the 
home because of the pain?        
3. Found it difficult to stand because 
of the pain?        
4. Found it difficult to sit because of the pain?   
     
5. Found it difficult to walk because of 
the pain?        
6. Found it difficult to exercise or do 
the leisure activities you would like 
to do because of the pain?       
7. Lost your appetite and/or been 
unable to eat because of the pain?       
 
  
15-OBE 2109- [ADDRESS_373043] YOU... 
 Never  Rarely  Sometimes  Often  Always  
8. Been unable to sleep properly 
because of the pain?        
9. Had to go to bed/lie down because of the pain?   
     
10. Been unable to do the things you 
want to do because of the pain?       
11. Felt unable to cope with the pain?       
12. Generally felt unwell?       
13. Felt frustrated because your symptoms are not getting better?   
     
14. Felt frustrated because you are not 
able to control your symptoms?        
 
  
15-OBE 2109- [ADDRESS_373044] YOU... 
 Never  Rarely  Sometimes  Often  Alwa ys 
15. Felt unable to forget your 
symptoms?        
16. Felt as though your symptoms are 
ruling your life?        
17. Felt your symptoms are taking 
away your life?        
18. Felt depressed?        
19. Felt weepy/tearful?       
20. Felt miserable?       
21. Had mood swings?       
22. Felt bad tempered or short 
tempered?        
 
  
15-OBE 2109- [ADDRESS_373045] YOU... 
 Never  Rarely  Sometimes  Often  Always  
23. Felt violent or aggressive?       
24. Felt unable to tell people how you 
feel?       
25. Felt others do not understand what you are going through?   
     
26. Felt as though others think you are 
moaning?        
27. Felt alone?       
28. Felt frustrated as you cannot 
always wear the clothes you would choose?  
     
29. Felt your appearance has been 
affec ted?       
30. Lacked confidence?        
 
  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 83 of 88 
 OBSEVA  CONFIDENTIAL  
 PATIENT GLOBAL IMPRES SION OF CHANGE    
 
 
  
 
 
Farrar JT, Young Jr. JP, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic 
pain intensity measured on an 11 -point numerical pain rating scale. Pain 2001; 94(2): 149 -158.  
 
 
  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 84 of 88 
 OBSEVA  CONFIDENTIAL  
 PI[INVESTIGATOR_304675] ® 
 
 
  

15-OBE 2109- [ADDRESS_373046] 
1. Eskenazi B, Warner M. Epi[INVESTIGATOR_304704]. Obstet Gyne col Clin North Am 
1997;24:235 –58. 
2. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362:2389 -98. Review.  
3. Fauconnier A, Chapron C. Endometriosis and pelvic pain: epi[INVESTIGATOR_304705]. Hum Reprod Update 2005;11:595 –606.  
4. Dunselman GA, Vermeulen N, Becker C, et al.  ESHRE guideline: man agement of women with 
endometr iosis. Hum Reprod 2014; 29:400– 12. 
5. Gao X, Outley J, Botteman M, et al . Economic burden of endometriosis. Fertil Steril. 
2006;86:1561- 72. Review.  
6. Nnoaham KE, Hummelshoj L, Webster P, et al.  World Endometriosis Research  Foundati on 
Global Study of Women's Health consortium. Impact of endometriosis on quality of life and 
work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96:[ADDRESS_373047] K, Lowton K, Wright J. What's the delay? A qualitative study of women's experiences 
of reaching a diagnosis of endometriosis. Fertil Steril. 2006;86:1296 -301.  
8. Husby [CONTACT_304759], Haugen RS, Moen MH. Diagnostic delay in women with pain and  endometriosis. 
Acta Obstet Gynecol Scand. 2003;82:649- 53. 
9. Hadfield R, Mardon H, Barlow D, et al . Delay in the diagnosis of endometriosis: a survey of 
women from the [LOCATION_003] and the [LOCATION_006]. Hum Reprod. 1996;11:878 -80. 
10. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus 
on current management of endometriosis. Hum Repro d. 2013;28:1552- 68. 
11. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010;116:223 -36. 
12. Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current and future medical therapi[INVESTIGATOR_014]. 
Best Pract Res Clin Obstet  Gynaecol. 2008;22:275 -306. Review.  
13. Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapi[INVESTIGATOR_304706]. Drugs.  2009;69:649 -75. Review . 
14. Meresman GF, Augé L, Barañao RI, et al.  Oral contraceptives suppress cell proliferat ion and 
enhance apoptosis of eutopic  endometrial tissue from patients with endometriosis. Fertil 
Steril. 2002;77:1141 -7. 
15. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic 
pain associated with endometriosis: a committ ee opi[INVESTIGATOR_1649]. Fertil Steril. 2014;101:927 -35. 
Erratum in: Fertil Steril. 2015;104:498.  
16. Schweppe KW. Current place of progestins in the treatment of endometriosis -related 
complaints. Gynecol Endocrinol. 2001;[ADDRESS_373048] 6:22 -8. Review.  
15-OBE 2109- 001 PROTOCOL V1.0 DATED 25 APRIL 2016  Page 88 of 88 
 OBSEVA  CONFIDENTIAL  17. Vercellini P, Fedele L, Pi[INVESTIGATOR_304707] G, et al.  Progestogens for endometriosis: forward to the past. 
Hum Reprod Update. 2003;9 :387 –96. 
18. Olive DL. Gonadotropin -releasing hormone agonists for endometriosis.  N Engl J Med. 
2008;359: 1136- 42. 
19. Ezzati M and Carr BR.  Elagolix, a novel, orally bioavailable GnRH antagonist under investigation 
for the treatment of endometriosis -related pain. Womens Health 2015 ;11:19– 28. 
20. Barbieri RL., Endometriosis and the estrogen threshold theory. Relation to surgical and medical 
treatm ent, J. Reprod, med. 1998 Mar, 43 ([ADDRESS_373049]) 287 –92. 
21. Riggs MM, Bennetts M, van der Graaf PH, Martin SW. Integrated pharmacometrics and 
systems pharmacology model- based analyses to guide GnRH receptor modulator 
development for management of endometriosis. CP T Pharmacometrics Syst Pharmacol. [ADDRESS_373050] 17;1:e11.  
22. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short -term 
and long- term effectiveness. Am J Obstet Gynecol. 1981;139:645 -54. 
23. Jones G, Jenkinson C, Taylor N, Mills A, Kenned y S. Measuring quality of life in women with 
endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of 
the Endometriosis Health Profile Questionnaire . Hum Reprod. 2006;10:2686 –93. 
24. Guy W. ECDEU assessment manual for p sychopharmacology. Washington, D.C.  : U.S. 
Government Printing Office, 1976.  
25. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in 
chronic pain intensity measured on an 11 -point numerical pain rating scale. Pain. 2001 ;94:149 -
58. 
26. FDA guidance for industry: Drug- Induced Liver Injury: Premarketing Clinical Evaluation. July 
2009.  
27. World Medical Association. World Medical Association Declaration of Helsinki: ethical 
principles for medical research involving human subjects. JAMA. 2013 ;310:2191 -4. 
 